antaranusa.com | berita nusantara internasional

Teva's Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO, AJOVY and UZEDY; Delivers Substantial Gross Margin Expansion

Tue, 03 Nov 2026 22:54:00 +0700

COMPANY STRENGTHENS NEUROSCIENCE LEADERSHIP WITH WELTRUZA LAUNCH AND STRATEGIC ADDITION OF BXCL-501

Q3 2026 revenues of $4.4 billion, a decrease of 2% year-over-year in both U.S. dollars and local currency terms, reflecting lower global generics revenues, primarily due to increased competition for lenalidomide capsules (a generic version of Revlimid) in the U.S. This decrease was partially offset by continued strong growth across Teva's key innovative brands.

Strong profitability: Gross profit margin was 55.5% in the third quarter of 2026, compared to 51.4% in the third quarter of 2025; non-GAAP gross profit margin increased to the highest quarterly level in the last decade, by 345 basis points to 58.7%, excluding the $500 million development milestone payments received for duvakitug (anti-TL1A) in Q4 2025; operating income was $714 million and non-GAAP operating income was $1,393 million; diluted earnings per share (EPS) was $0.20 and non-GAAP diluted EPS was $0.86; cash flow generated from operating activities was $241 million and free cash flow was approximately $0.5 billion.

Key innovative brands continued to drive Teva's portfolio transformation, collectively generating approximately $1.1 billion in revenues and growing 33% year-over-year in local currency:

AUSTEDO global revenues were $751 million, increasing 21% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $2.55 billion-$2.65 billion, from $2.45 billion-$2.60 billion.

AJOVY global revenues were $269 million, increasing 61% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $930 million-$960 million, from $850 million-$870 million.

UZEDY revenues were $85 million, increasing 96% year-over-year in local currency. Teva is raising its 2026 revenue outlook to $290 million?$310 million, from $270 million-$290 million.

Building the next wave of neuroscience growth: Teva received FDA approval for WELTRUZA in the U.S. in October 2026, marking a significant expansion for long-acting injectable schizophrenia treatment and highlighting Teva's established commercial capabilities and deep understanding of the patient journey. The Company continues to target LAI schizophrenia portfolio (UZEDY and WELTRUZA) with peak sales potential of $1.5 billion-$2.0 billion.

Expanding Teva's growth through strategic business development:

Acquired BXCL-501, from BioXcel Therapeutics Inc., which is under FDA review for potential at-home use for the acute treatment agitation associated with schizophrenia or bipolar I or II disorder in adults;

Deepened collaboration with Samsung Bioepis for the commercialization of two additional biosimilars, infliximab-abda, a biosimilar to Remicade? (infliximab), and etanercept-ykro, a biosimilar to Enbrel (etanercept), expanding the Company's burgeoning global pipeline and portfolio of biosimilars.

Generics and biosimilars remain an important foundation: global generics revenues decreased 16% year-over-year in local currency, primarily reflecting lower U.S. revenues from lenalidomide capsules (a generic version of Revlimid), partially offset by recently launched generic products and growth in biosimilars. Teva's biosimilars business continued to expand and is currently expected to exceed $0.8 billion in 2026 revenues, achieving our original 2027 revenue objective one year ahead of plan.

Innovative pipeline successes strengthen Teva's longer-term growth profile with the potential to launch at least one product per year over five years:

The U.S. FDA accepted the ecopipam New Drug Application (NDA) for review, advancing a potential first-in-class selective D1 receptor anti-agonist for Tourette syndrome in the pediatric population, with an action date expected in Q1 2027.

Teva reported positive Phase 2a results for anti-IL-15 (TEV-駰) in Celiac disease, and is targeting to begin Phase 2b in vitiligo in Q4 2026.

Teva discontinued its phase 2 Multiple System Atrophy (MSA) study of emrusolmin (TEV-饶), following an interim futility analysis that indicated low probability of the study meeting its primary efficacy endpoint if continued.

Financial strength, with continued value creation for shareholders: the return to an investment grade credit rating, refinancing of ~$4.9 billion in debt during Q3 2026, and the direct listing of Teva's ordinary shares on the New York Stock Exchange (NYSE); all reflect Teva's strong execution of its Pivot to Growth strategy, continued financial strength and long-term shareholder value creation.

Finalized Most-Favored-Nation (MFN) agreement with the U.S. Administration, including a prospective pricing commitment with respect to certain future innovative product launches.

Q3 2026 Highlights:

Revenues of $4.4 billion (-2% YoY)

GAAP diluted EPS of $0.20 (-47% YoY); non-GAAP diluted EPS of $0.86 (+10% YoY) includes $0.02 of acquired IPR&D charges

GAAP net income of $233 million; Adjusted EBITDA of $1.5 billion (+7% YoY)

Cash flow generated from operating activities of $241 million; Free cash flow of $495 million (-4% YoY)

GAAP gross profit margin of 55.5%; non-GAAP gross profit margin of 58.7%, an increase of 345 basis points year-over-year, the highest quarterly level in the last decade when excluding the $500 million development milestone payments received for duvakitug (anti-TL1A) in Q4 2025

2026 Business Outlook - Innovative brand revenues outlook increased, non-GAAP operating income outlook increased for underlying operational performance, offset by increased IPR&D*:

Revenues: $16.7-$17.0 billion

Non-GAAP operating income: $3.8-$3.9 billion; includes $0.87 billion of acquired IPR&D charges

Adjusted EBITDA: $4.23-$4.43 billion; includes $0.87 billion of acquired IPR&D charges

Non-GAAP diluted EPS: $1.92$-2.11; includes $0.71 of acquired IPR&D charges

Free cash flow: $2.1-$2.4 billion

AUSTEDO revenues: $2.55 billion-$2.65 billion

AJOVY revenues: $930 million-$960 million

UZEDY revenues: $290 million-$310 million

*IPR&D impact is presented due to uncertainty of the future occurrence and timing of these transactions

TEL AVIV, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2026.

Richard Francis, Teva's President and CEO, said: "Our strong third-quarter performance is another clear demonstration of Pivot to Growth in action and how far Teva has come. The FDA approval of WELTRUZA has further advanced our innovative portfolio, our recently announced biosimilars agreement with Samsung Bioepis has strengthened our generics powerhouse and our return to investment grade reflects the transformation of our financial position. Together, these achievements represent how we are delivering sustained innovative growth and translating that growth into greater profitability, with our three key innovative brands collectively growing 33% in local currency to approximately $1.1 billion year-over-year. This performance, together with continued margin expansion and cash flow generation, gives us the confidence to raise our 2026 revenue outlook for all three brands."

Mr. Francis added: "At the same time, we are continuously building the next phase of sustainable growth at Teva. The U.S. launch of WELTRUZA expands our schizophrenia franchise, while progress across ecopipam, anti-IL-15 and our broader late-stage pipeline supports our ambition to deliver at least five potential innovative launches over five years. Our return to investment grade and debt refinancing reflect our strengthened financial position."

Pivot to Growth Strategy

In the third quarter of 2026 and into October 2026, Teva continued to execute on the four pillars of its Pivot to Growth strategy:

Delivering on our growth engines

Teva's key innovative brands, AUSTEDO, AJOVY and UZEDY, collectively generated approximately $1.1 billion in revenues and grew 33% year-over-year in local currency. Strong performance across all three brands supports increased 2026 revenue outlooks of these products and continues to shift Teva's portfolio toward innovative medicines. The FDA approval and U.S. launch of WELTRUZA further expand Teva's long-acting injectable schizophrenia portfolio and builds on the commercial momentum established by UZEDY.

Stepping up innovation

Teva continued to advance a differentiated late-stage pipeline across neuroscience and immunology. The FDA accepted ecopipam's (EBS-101) NDA for review, positive Phase 2a results were reported for anti-IL-15 (TEV-駰) in Celiac disease, and the anti-IL-15 program is planned to advance into Phase 2b development in vitiligo later this year. Together with the acquisition of BXCL-501 (dexmetomidine sublingual film) from BioXcel Therapeutics, these milestones expand Teva's capabilities in areas of significant unmet need and support its ambition to deliver a sustained cadence of potential launches.

Sustaining our generics powerhouse

Teva continues to strengthen its global generics business through an increased focus on complex generics and biosimilars. While global generics revenues declined primarily due to lower revenues of lenalidomide capsules (a generic version of Revlimid?) in the U.S., revenues from biosimilars continued to expand. Teva currently expects more than $0.8 billion in biosimilars revenues in 2026, reaching its original 2027 revenue objective one year early, with further portfolio expansion supported by new collaborations, including the recently announced agreement with Samsung Bioepis.

Focusing our business

Teva continued to transform and modernize its business through the Teva Transformation programs, which combined with innovative product growth potential, is expected to support the Company's objective of achieving a 30% non-GAAP operating income margin and approximately $700 million of net savings, by 2027 including -two-thirds expected to be realized in 2026. At the same time, Teva continued to maintain disciplined capital allocation and strengthen its financial profile. During Q3 2026, Moody's and S&P upgraded Teva to investment grade, following Fitch's earlier upgrade; and Teva refinanced ~$4.9 billion of debt. All these reflect Teva's goal to achieve two times debt leverage by the end of 2027.

Third Quarter 2026 Consolidated Results

Revenues in the third quarter of 2026 were $4,395 million, a decrease of 2% in both U.S. dollars and local currency terms compared to the third quarter of 2025. This decrease was mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid?) in our U.S. segment, partially offset by higher revenues from our key innovative products, primarily AUSTEDO, AJOVY and UZEDY.

Exchange rate movements in the third quarter of 2026, net of hedging effects, positively impacted revenues by $5 million, compared to the third quarter of 2025.

Gross profit in the third quarter of 2026 was $2,440 million, an increase of 6% compared to $2,304 million in the third quarter of 2025. Gross profit margin was 55.5% in the third quarter of 2026, compared to 51.4% in the third quarter of 2025. Non-GAAP gross profit was $2,580 million in the third quarter of 2026, an increase of 4% compared to $2,475 million in the third quarter of 2025. Non-GAAP gross profit margin was 58.7% in the third quarter of 2026, compared to 55.3% in the third quarter of 2025. The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to a favorable mix of products, primarily higher revenues from our key innovative products, largely AUSTEDO, partially offset by lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid).

Research and Development (R&D) expenses, net in the third quarter of 2026, were $297 million, an increase of 16% compared to $256 million in the third quarter of 2025. This increase was mainly due to higher expenses in our immunology and neuroscience projects, as well as in our biosimilars pipeline. Our R&D expenses, net in the third quarters of 2026 and 2025, were also impacted by reimbursements and cost sharing from our strategic partnerships and collaborations entered into in recent years.

Selling and Marketing (S&M) expenses in the third quarter of 2026, were $709 million, an increase of 8% compared to the third quarter of 2025. This increase was mainly due to promotional activities related to our key innovative products, primarily AUSTEDO, and other innovative product launch preparation activities in our U.S. segment.

General and Administrative (G&A) expenses in the third quarter of 2026 were $298 million, a decrease of 6% compared to the third quarter of 2025.

Other Income in the third quarter of 2026 was $68 million, compared to other loss of $7 million in the third quarter of 2025, mainly related to a capital gain from the sale of a property in Europe.

Operating Income was $714 million in the third quarter of 2026, compared to an operating income of $882 million in the third quarter of 2025. Operating Income as a percentage of revenues was 16.2% in the third quarter of 2026, compared to 19.7% in the third quarter of 2025. This decrease was mainly due to higher tangible asset impairments and higher legal settlements and loss contingencies, partially offset by an increase in gross profit. Non-GAAP operating income in the third quarter of 2026 was $1,393 million representing a non-GAAP operating margin of 31.7% compared to $1,294 million representing 28.9%, respectively, in the third quarter of 2025. This increase in non-GAAP operating margin in the third quarter of 2026 was mainly due to higher gross profit margin as described above.

Exchange rate movements in the third quarter of 2026, net of hedging effects, had a negative impact of $2 million on our operating income and non-GAAP operating income compared to the third quarter of 2025.

Financial expenses, net in the third quarter of 2026, were $414 million, mainly comprised of a loss of $224 million on extinguishment of debt and net interest expenses of $174 million. In the third quarter of 2025, financial expenses, net were $237 million, mainly comprised of net interest expenses of $209 million.

In the third quarter of 2026, we recognized a tax expense of $66 million on pre-tax income of $300 million. In the third quarter of 2025, we recognized a tax expense of $214 million on pre-tax income of $646 million.

Our tax rate in the third quarter of 2026 was 22.1%, compared to 33.1% in the third quarter of 2025. Non-GAAP tax rate in the third quarter of 2026 was 16.5%, compared to 14.7% in the third quarter of 2025. Our tax rate and non-GAAP tax rate in the third quarter of 2026 were mainly affected by the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate and other infrequent or non-recurring items. Our tax rate and non-GAAP tax rate in the third quarter of 2025 were mainly affected by changes in deferred tax balances due to statutory tax rate changes and interest and inflation adjustments related to the agreement with the Israeli Tax Authorities.

Considering the above, we expect our annual non-GAAP tax rate for 2026 to be between 20%-23%, higher than our non-GAAP tax rate for 2025, which was 15.8%.

Net income attributable to Teva and diluted earnings per share in the third quarter of 2026 were $233 million and $0.20, respectively, compared to net income attributable to Teva and diluted earnings per share of $433 million and $0.37, respectively, in the third quarter of 2025. This decrease was mainly due to lower operating income, as discussed above. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share in the third quarter of 2026 were $1,013 million and $0.86, respectively, compared to $910 million and $0.78, respectively, in the third quarter of 2025.

Adjusted EBITDA was $1,496 million in the third quarter of 2026, an increase of 7%, compared to $1,394 million in the third quarter of 2025.

As of September 30, 2026 and 2025, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,195 million shares and 1,184 million shares, respectively.

Non-GAAP information: non-GAAP adjustments in the third quarter of 2026 were $780 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the third quarter of 2026 were adjusted to exclude the following items:

Amortization of purchased intangible assets of $139 million, of which $129 million is included in cost of sales and the remaining $9 million in S&M expenses;

Legal settlements and loss contingencies of $201 million;

Restructuring expenses of $58 million;

Impairment of long-lived assets of $228 million;

Contingent consideration expenses of $2 million;

Equity compensation expenses of $38 million;

Financial expenses of $235 million;

Other non-GAAP items of $14 million; and

Corresponding tax effects and unusual tax items of $134 million.

We believe that excluding such items facilitates investors' understanding of our business including underlying trends, thereby improving the comparability of our business performance results between reporting periods.

For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below and the information included under "Non-GAAP Financial Measures." Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP.

Cash flow generated from operating activities during the third quarter of 2026 was $241 million compared to $369 million in the third quarter of 2025. The lower cash flow generated from operating activities in the third quarter of 2026 resulted mainly from the timing of sales and collections, partially offset by lower legal settlement payments.

During the third quarter of 2026, we generated free cash flow of $495 million, which we define as comprising: $241 million in cash flow generated from operating activities, $327 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $47 million of proceeds from the sale of businesses and long-lived assets, partially offset by $120 million in cash used for capital investments. During the third quarter of 2025, we generated free cash flow of $515 million, which we define as comprising $369 million in cash flow generated from operating activities, $274 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $8 million of proceeds from the sale of businesses and long-lived assets, partially offset by $136 million in cash used for capital investments. The decrease in the third quarter of 2026 resulted mainly from lower cash flow generated from operating activities, as discussed above, partially offset by higher proceeds from the sale of businesses and long-lived assets.

As of September 30, 2026, our debt was $16,718 million, compared to $16,807 million as of December 31, 2025. This decrease was mainly due to $256 million of exchange rate fluctuations. In addition, during the third quarter of 2026, we consummated an early redemption of $4,678 million in aggregate principal amount of senior notes and concurrently, issued $4,837 million of new senior notes, net of discount and issuance costs. The portion of total debt classified as short-term as of September 30, 2026 was 24% compared to 11% as of December 31, 2025. Our financial leverage, which is the ratio between our debt and the sum of our debt and equity, was 68% as of September 30, 2026 and December 31, 2025. Our average debt maturity was approximately 6.3 years as of September 30, 2026, compared to 5.6 years as of December 31, 2025.

Segment Results for the third quarter of 2026

United States Segment

In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. This shift allows the United States segment to continue to manage its entire product portfolio in the region, while strengthening focus on its biopharmaceutical business, growth engines and innovation. As a result, from that date, Anda is reported as part of the Company's Other Activities. Prior period amounts were recast to reflect this change.

The following table presents revenues, expenses and profit for our United States segment for the three months ended September 30, 2026 and 2025:

Three months ended September 30,
	2026			2025
	(U.S. $ in millions / % of Segment Revenues)
Revenues	$	1,870	100 %	$	2,090	100 %
Cost of sales	467		25.0 %	645		30.9 %
Gross profit	1,403		75.0 %	1,446		69.1 %
R&D expenses	196		10.5 %	161		7.7 %
S&M expenses	306		16.4 %	248		11.8 %
G&A expenses	109		5.9 %	113		5.4 %
Other	?		?	(3)		?
Segment profit*	$	791	42.3 %	$	927	44.3 %

_______________________
* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million or 0.5% as applicable.

Revenues from our United States segment in the third quarter of 2026 were $1,870 million, a decrease of 11% compared to the third quarter of 2025, mainly due to lower revenues from generic products, primarily lenalidomide capsules (a generic version of Revlimid?), partially offset by higher revenues from our key innovative products, primarily AUSTEDO, AJOVY, and UZEDY.

Revenues by Major Products and Activities

The following table presents revenues for our United States segment by major products and activities for the three months ended September 30, 2026 and 2025:

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)

Generic products (including biosimilars)	$	718	$	1,175	(39)%
AJOVY	138		73		88%
AUSTEDO	727		601		21%
BENDEKA and TREANDA	30		35		(15)%
COPAXONE	58		62		(8)%
UZEDY	85		43		96%
Other	114		101		13%
Total	$	1,870	$	2,090	(11)%

Generic products (including biosimilar products) revenues in our United States segment in the third quarter of 2026 were $718 million, a decrease of 39% compared to the third quarter of 2025. This decrease was mainly driven by lower revenues from lenalidomide capsules (a generic version of Revlimid) due to increased generic competition in the U.S., partially offset by higher revenues from our portfolio of biosimilar products and from recently launched generic products.

Among the most significant generic products we sold in the United States in the third quarter of 2026 were epinephrine injectable solution (a generic equivalent of EpiPen and EpiPen Jr), TRUXIMA (a biosimilar to Rituxan), and SIMLANDI (a biosimilar to Humira). In the third quarter of 2026, our total prescriptions were approximately 227 million (based on trailing twelve months), representing 5.8% of total U.S. generic prescriptions, compared to approximately 261 million (based on trailing twelve months), representing 6.7% of total U.S. generic prescriptions in the third quarter of 2025, all according to IQVIA data.

On September 28, 2026, we announced that the FDA approved DEGEVMA (denosumab-adet) as a biosimilar to Xgeva (denosumab). DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone, and for the treatment of hypercalcemia of malignancy.

AJOVY revenues in our United States segment in the third quarter of 2026 were $138 million, an increase of 88% compared to the third quarter of 2025, mainly due to a reduction in sales allowance as well as growth in volume. In the third quarter of 2026, AJOVY's exit market share in the United States in terms of total number of prescriptions was 32.8% out of the subcutaneous injectable anti-CGRP class, compared to 32.2% in the third quarter of 2025.

AUSTEDO revenues (which include AUSTEDO XR) in our United States segment in the third quarter of 2026 were $727 million, an increase of 21%, compared to the third quarter of 2025. This increase was mainly due to growth in volume and a favorable business mix including improved net-price realization.

AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023. The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in 18 mg in July 2024. AUSTEDO XR is a once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington's disease, which is additional to the twice-daily AUSTEDO.

UZEDY (risperidone) extended-release injectable suspension revenues in our United States segment in the third quarter of 2026 were $85 million, an increase of 96% compared to the third quarter of 2025, mainly due to growth in volume.

On October 9, 2026, we announced that the FDA approved WELTRUZA (olanzapine) for extended-release injectable suspension, a new once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. WELTRUZA is expected to become available in the U.S. in the coming weeks, in three different strengths (318 mg, 425 mg, 531 mg). In May 2026, the European Medicines Agency accepted Teva's Marketing Authorization Application for olanzapine LAI (TEV-'749). WELTRUZA is protected in the U.S. by four Orange Book listed patents expiring between 2033 and 2044, and in Europe by five granted patents expiring between 2031 and 2044.

BENDEKA and TREANDA combined revenues in our United States segment in the third quarter of 2026 were $30 million, a decrease of 15% compared to the third quarter of 2025, mainly due to competition from alternative therapies, as well as from branded and generic bendamustine products.

COPAXONE revenues in our United States segment in the third quarter of 2026 were $58 million, a decrease of 8% compared to the third quarter of 2025.

United States Gross Profit

Gross profit from our United States segment in the third quarter of 2026 was $1,403 million, a decrease of 3%, compared to the third quarter of 2025.

Gross profit margin for our United States segment in the third quarter of 2026 increased to 75.0%, compared to 69.1% in the third quarter of 2025. This increase was mainly due to a favorable mix of products, primarily higher revenues from our key innovative products, largely AUSTEDO, partially offset by lower revenues from lenalidomide capsules (a generic version of Revlimid?).

United States Profit

Profit from our United States segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profit from our United States segment in the third quarter of 2026 was $791 million, a decrease of 15% compared to $927 million in the third quarter of 2025. This decrease was mainly due to higher S&M expenses and lower gross profit, as discussed above.

Europe Segment

Our Europe segment includes the European Union, the United Kingdom and certain other European countries.

The following table presents revenues, expenses and profit for our Europe segment for the three months ended September 30, 2026 and 2025:

Three months ended September 30,
	2026			2025
	(U.S. $ in millions / % of Segment Revenues)
Revenues	$	1,319	100 %	$	1,235	100 %
Cost of sales	562		42.6 %	570		46.1 %
Gross profit	757		57.4 %	665		53.9 %
R&D expenses	62		4.7 %	62		5.0 %
S&M expenses	211		16.0 %	225		18.2 %
G&A expenses	64		4.8 %	75		6.1 %
Other	?		?	?		?
Segment profit*	$	420	31.8 %	$	303	24.5 %

_______________________
* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million or 0.5%, as applicable.

Revenues from our Europe segment in the third quarter of 2026 were $1,319 million, an increase of 7% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This increase was mainly due to higher revenues from generic products, higher proceeds from the sale of certain product rights, and higher revenues from AJOVY.

In the third quarter of 2026, revenues were negatively impacted by exchange rate fluctuations of $7 million, net of hedging effects, compared to the third quarter of 2025. Revenues in the third quarter of 2026 included $17 million from a positive hedging impact, compared to $6 million in the third quarter of 2025, which are included in "Other" in the table below.

Revenues by Major Products and Activities

The following table presents revenues for our Europe segment by major products and activities for the three months ended September 30, 2026 and 2025:

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)

Generic products (including OTC and biosimilars)	$	1,033	$	982	5%
AJOVY	84		66		28%
COPAXONE	38		44		(12)%
Respiratory products	54		52		3%
Other*	111		91		21%
Total	$	1,319	$	1,235	7%

_______________________
* Other revenues in the third quarters of 2026 and 2025 include the sale of certain product rights.

Generic products revenues (including OTC and biosimilar products) in our Europe segment in the third quarter of 2026 were $1,033 million, an increase of 5% compared to the third quarter of 2025. In local currency terms, revenues increased by 7%, mainly due to higher sales of generic and OTC products, including from recently launched products.

AJOVY revenues in our Europe segment in the third quarter of 2026 were $84 million, an increase of 28% compared to the third quarter of 2025. In local currency terms revenues increased by 29% mainly due to higher volumes.

COPAXONE revenues in our Europe segment in the third quarter of 2026 were $38 million, a decrease of 12% compared to the third quarter of 2025. In local currency terms revenues decreased by 11%, mainly due to price reductions and lower volumes resulting from the availability of alternative therapies.

Respiratory products revenues in our Europe segment in the third quarter of 2026 were $54 million, an increase of 3% compared to the third quarter of 2025. In local currency terms, revenues increased by 4%, mainly due to higher volumes as a result of increased supply.

Europe Gross Profit

Gross profit from our Europe segment in the third quarter of 2026 was $757 million, an increase of 14% compared to the third quarter of 2025. Gross profit margin for our Europe segment in the third quarter of 2026 increased to 57.4%, compared to 53.9% in the third quarter of 2025. This increase was mainly due to higher proceeds from the sale of certain product rights and a positive impact from hedging activities.

Europe Profit

Profit from our Europe segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profit from our Europe segment in the third quarter of 2026 was $420 million, an increase of 39%, compared to the third quarter of 2025. This increase was mainly due to higher gross profit, as discussed above.

International Markets Segment

Our International Markets segment includes all countries in which we operate other than the United States and the countries included in our Europe segment. The International Markets segment covers a substantial portion of the global pharmaceutical industry, including more than 35 countries. The countries in our International Markets segment include highly regulated, mainly generic markets, such as Canada and Israel, and branded generics-oriented markets, such as Russia and certain Latin America markets.

As of the date of this Quarterly Report on Form 10-Q, sustained conflict between Russia and Ukraine and disruption in the region is ongoing. Russia and Ukraine markets are included in our International Markets segment results and we have no manufacturing or R&D facilities in these markets. In September 2026, a warehouse that we share with other pharmaceutical companies in Ukraine was damaged, and, as of the date of this Quarterly Report on Form 10-Q, operations at this warehouse resumed. The impact of this conflict on our International Markets segment in the third quarter of 2026 was immaterial.

The following table presents revenues, expenses and profit for our International Markets segment for the three months ended September 30, 2026 and 2025:

	Three months ended September 30,
	2026			2025
	(U.S. $ in millions / % of Segment Revenues)

Revenues	$	592	100 %	$	557	100 %
Cost of sales	276		46.7 %	280		50.2 %
Gross profit	316		53.3 %	278		49.8 %
R&D expenses	31		5.3 %	26		4.6 %
S&M expenses	125		21.2 %	122		21.9 %
G&A expenses	34		5.7 %	36		6.4 %
Other	?		?	?		?
Segment profit*	$	125	21.1 %	$	95	17.0 %

_______________________
* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million or 0.5%, as applicable.

Revenues from our International Markets segment in the third quarter of 2026 were $592 million, an increase of 6% compared to the third quarter of 2025. In local currency terms, revenues increased by 4% compared to the third quarter of 2025, mainly due to higher revenues from our key innovative products AJOVY and AUSTEDO.

In the third quarter of 2026, revenues were positively impacted by exchange rate fluctuations of $13 million, including hedging effects, compared to the third quarter of 2025. Revenues in the third quarter of 2026 included $7 million from a positive hedging impact, compared to $2 million in the third quarter of 2025, which are included in "Other" in the table below.

Revenues by Major Products and Activities

The following table presents revenues for our International Markets segment by major products and activities for the three months ended September 30, 2026 and 2025:

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)

Generic products (including OTC and biosimilars)	$	407	$	421	(3)%
AJOVY	48		30		61%
AUSTEDO	24		17		42%
COPAXONE	8		8		8%
Other*	105		82		28%
Total	$	592	$	557	6%

_______________________
*Other revenues in the third quarters of 2026 and 2025 include the sale of certain product rights.

Generic products revenues (including OTC and biosimilar products) in our International Markets segment in the third quarter of 2026 were $407 million, a decrease of 3% compared to the third quarter of 2025. In local currency terms, revenues decreased by 4%, mainly due to lower revenues from generic and OTC products in certain markets including Ukraine.

AJOVY revenues in our International Markets segment in the third quarter of 2026 were $48 million, an increase of 61% in both U.S. dollars and local currency terms compared to the third quarter of 2025. This increase was mainly due to growth in multiple markets. In April 2026, we announced a strategic partnership for the marketing and distribution of AJOVY in China with Nuerogen (Zhuhai) Pharmaceutical Company Ltd.

AUSTEDO revenues in our International Markets segment in the third quarter of 2026 were $24 million, an increase of 42% compared to the third quarter of 2025. In local currency terms, revenue increased by 34% compared to the third quarter of 2025, mainly due to growth in China.

COPAXONE revenues in our International Markets segment in the third quarter of 2026 were $8 million, an increase of 8% compared to the third quarter of 2025.

International Markets Gross Profit

Gross profit from our International Markets segment in the third quarter of 2026 was $316 million, an increase of 14% compared to the third quarter of 2025.

Gross profit margin for our International Markets segment in the third quarter of 2026 increased to 53.3%, compared to 49.8% in the third quarter of 2025. This increase was mainly due to a favorable mix of products, primarily attributed to higher revenues from AJOVY and AUSTEDO, partially offset by lower revenues from generic products, as discussed above.

International Markets Profit

Profit from our International Markets segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items.

Profit from our International Markets segment in the third quarter of 2026 was $125 million, an increase of 32%, compared to the third quarter of 2025. This increase was mainly due to higher gross profit, as discussed above.

Other Activities

We have other sources of revenues, primarily our distribution business in the United States to third parties through Anda, the sale of APIs to third parties, an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis, and certain contract manufacturing services. Our Other Activities are not included in our United States, Europe or International Markets segments described above.

In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. As a result, from that date, Anda is reported as part of our Other Activities. Prior period amounts were recast to reflect this change.

In 2024, we announced that we intend to divest our API business (including its R&D, manufacturing and commercial activities) through a sale. The intention to divest is in alignment with our Pivot to Growth strategy, and Teva is conducting a sales process for this matter. However, there can be no assurance regarding the ultimate timing or structure of a potential divestiture or that a divestiture will be completed at all.

Our revenues from Other Activities in the third quarter of 2026 were $613 million, an increase of 3% in both U.S. dollars and local currency terms, compared to the third quarter of 2025.

Anda revenues from third-party products in the third quarter of 2026 were $401 million, an increase of 2%, compared to the third quarter of 2025, mainly due to higher volumes. Anda, our distribution business in the United States, operates independently and distributes generic and innovative medicines and OTC pharmaceutical products from various manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda competes in the distribution market by maintaining a broad portfolio of products, competitive pricing and delivery throughout the United States.

API sales to third parties in the third quarter of 2026 were $115 million, a decrease of 8% in both U.S. dollars and local currency terms, compared to the third quarter of 2025. This decrease was mainly due to lower demand resulting from market dynamics and temporary supply challenges.

Revenues from additional other activities, mainly from Medis and certain contract manufacturing services, were $98 million in the third quarter of 2026, an increase of 21% in U.S. dollars, or 23% in local currency terms compared to the third quarter of 2025, mainly due to higher demand.

2026 Financial Outlook

$ billions, except diluted EPS or as noted	Prior Guidance	Updated Guidance	Key Assumptions
Revenues	$16.5 - $16.85	$16.7 - $17.0	Assume growth in innovative products
AUSTEDO ($m)	2,450 - 2,600	2,550 - 2,650
AJOVY ($m)	850 - 870	930 - 960
UZEDY ($m)	270 - 290	290 - 310
Operating Income*	3.8 - 4.0	3.8 - 3.9	Increase of $0.05B before updating guidance for $0.1B impact of acquired IPR&D charge
Adjusted EBITDA*	4.23 - 4.53	4.23 - 4.43
Finance Expenses*	~$0.8	~$0.8
Tax Rate*	20% - 23%	20% - 23%
Diluted EPS* ($)	1.91 - 2.11	1.92 - 2.11	Increase of $0.08 at midpoint before updating guidance for $0.07 impact of acquired IPR&D charge
Free Cash Flow*	2.0 - 2.4	2.1 - 2.4
CAPEX	0.5	0.5
Foreign Exchange	Volatile swings in FX can negatively impact revenue and income

Financial guidance only assumes business development transactions closed as of November 3, 2026.

*Certain items above are non-GAAP financial measures. For more information, see "Non-GAAP Financial Measures" below. Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables.

Conference Call

Teva will host a conference call and live webcast along with a slide presentation on Tuesday, November 3, 2026 at 8:00 a.m. ET to discuss its third quarter 2026 financial results and overall business environment.

A question & answer session will follow.

In order to participate, please register in advance here to obtain a local or toll‐free phone number and your personal pin.

A live webcast of the call will be available on Teva's website at: www.tevapharm.com

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts.

Non-GAAP Financial Measures

This press release contains certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures, including, but not limited to, non-GAAP operating income, non-GAAP operating margin, non-GAAP gross profit, non-GAAP gross profit margin, Adjusted EBITDA, free cash flow, non-GAAP tax rate, non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS, are presented in order to facilitate investors' understanding of our business. We utilize certain non-GAAP financial measures to evaluate performance in conjunction with other performance metrics. The following are examples of how we utilize the non-GAAP measures: our management and board of directors use the non-GAAP measures to evaluate our operational performance and, to compare our results against work plans and budgets, and ultimately to evaluate the performance of management; our annual budgets are prepared on a non-GAAP basis; and senior management's annual compensation is derived, in part, using these non-GAAP measures. See the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP measures. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing the most comparable forward-looking GAAP measures for non-GAAP metrics included in our financial outlook or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP.

Cautionary Note Regarding Forward-Looking Statements

our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; competition faced by our generic medicines from other pharmaceutical companies; changes in regulatory policy that may result in costs and delays; delays in launches of new generic products; our ability to develop and commercialize additional pharmaceutical products in a timely manner; intense competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline, to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights;
our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all;
our business and operations in general, including: the impact of global geopolitical, economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and our exposure to changes in international trade policies, including the imposition of tariffs in the jurisdictions in which we operate and their effects, and effects related to the agreement we entered into with the U.S. Administration in October 2026, on the pricing and sales of our products, manufacturing and the availability of raw materials; effectiveness of our optimization efforts; significant disruptions of information technology systems, including cybersecurity attacks, as well as risks and uncertainties related to the adoption of artificial intelligence technologies, and breaches of our data security; interruptions in our supply chain or problems with internal or third party manufacturing; challenges associated with conducting business globally, including political or economic instability, prolonged government shutdowns, widespread outbreaks of major diseases and major hostilities or acts of terrorism, such as the ongoing conflict in the Middle East and war involving Iran, and the international responses including economic, trade, financial or other restrictive measures directed specifically at Israel or Israeli companies, and the war between Russia and Ukraine; our ability to attract, hire, integrate and retain highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and/or integrate acquisitions successfully and cost-effectively; and our prospects and opportunities for growth if we sell or plan to sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively effectuate and consummate such sales and divestitures, including our planned divestiture of our API business;
compliance, regulatory and litigation matters, including: ongoing legal proceedings, legal settlements and loss contingencies, any failure to comply with complex legal and regulatory requirements, the effects of regulatory uncertainty and changes and the results of increased regulatory oversight, including expenditures required to ensure compliance with research, production and quality control regulations and remedial actions taken to address product issues, such as delayed product launches, product recalls, and facility shutdowns; the effects of governmental, regulatory and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare regulation and related reductions in pharmaceutical pricing, reimbursement and coverage, including as a result of the One Big Beautiful Bill signed into law in the U.S. in July 2025 ("OBBBA"), which will likely reduce the number of insured in Medicaid and Health Insurance Exchange markets, potentially altering utilization patterns and shifting negotiating leverage among payors, our October 2026 agreement with the U.S. Administration referenced above, which followed U.S. Executive Orders issued in April and May 2025 intended to reduce the prices paid for prescription medicines, including Most-Favored-Nation pricing; legal and regulatory actions in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan? (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to comply with and operate under our deferred prosecution agreement ("DPA") with the U.S. Department of Justice ("DOJ"); potential liability for intellectual property right infringement; significant product liability claims; claims brought by regulatory agencies; failure to comply with complex Medicare, Medicaid and other governmental programs' reporting and payment obligations; compliance with sanctions and trade control laws; environmental risks; and the impact of sustainability issues;
financial, economic and other risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; impairments of our long-lived assets; potential significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; the impact of any failure to maintain effective internal control over our financial reporting; our ability to successfully implement the process for terminating our ADS program and directly listing our ordinary shares in lieu of the ADSs (the "Conversion") and achieve our aims as a result of such Conversion, as further described in Part II, Item 5 our Quarterly Report on Form 10-Q and on our website at ir.tevapharm.com; and;

other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Consolidated Statements of Income
(U.S. dollars in millions, except share and per share data)
(Unaudited)

			Three months ended				Nine months ended
			September 30,				September 30,
			2026		2025		2026		2025
Net revenues		$	4,395	$	4,480	$	12,519	$	12,547
Cost of sales			1,955		2,176		5,954		6,264
Gross profit			2,440		2,304		6,565		6,282
Research and development expenses			297		256		1,489		746
Selling and marketing expenses			709		656		2,122		1,933
General and administrative expenses			298		317		919		920
Intangible assets impairments			24		64		54		227
Other asset impairments, restructuring and other items			264		62		438		272
Legal settlements and loss contingencies			202		60		504		312
Other loss (income)			(68)		7		(96)		15
Operating income (loss)			714		882		1,135		1,857
Financial expenses, net			414		237		854		714
Income (loss) before income taxes			300		646		282		1,143
Income taxes (benefit)			66		214		254		210
Share in (profits) losses of associated companies, net			*		(2)		*		(4)
Net income (loss)			234		434		27		937
Net income (loss) attributable to redeemable and non-redeemable non-controlling interest			1		1		1		7
Net income (loss) attributable to Teva			233		433		26		930

Earnings (loss) per share attributable to Teva:	Basic	$	0.20	$	0.38	$	0.02	$	0.81
	Diluted	$	0.20	$	0.37	$	0.02	$	0.80
Weighted average number of shares (in millions):	Basic		1,166		1,147		1,162		1,144
	Diluted		1,183		1,164		1,180		1,160

Non-GAAP net income attributable to Teva for diluted earnings per share:**			1,013		910		1,655		2,281
Non-GAAP earnings per share attributable to Teva:**	Diluted	$	0.86	$	0.78	$	1.40	$	1.97

Non-GAAP average number of shares (in millions):	Diluted		1,183		1,164		1,180		1,160


Amounts may not add up due to rounding.

* Represents an amount less than $0.5 million.
** See reconciliation attached.

CONSOLIDATED BALANCE SHEETS
(U.S. dollars in millions, except for share data)
(Unaudited)

	September 30,		December 31,
	2026		2025
ASSETS
Current assets:
Cash and cash equivalents	$	4,085	$	3,556
Accounts receivables, net of allowance for credit losses of $71 million and $81 million as of September 30, 2026 and December 31, 2025, respectively.		3,837		3,709
Inventories		3,173		3,179
Prepaid expenses		1,014		1,122
Other current assets		658		539
Assets held for sale		1,836		1,842
Total current assets		14,602		13,946
Deferred income taxes		2,057		2,191
Other non-current assets		269		405
Property, plant and equipment, net		3,747		4,080
Operating lease right-of-use assets, net		321		345
Identifiable intangible assets, net		3,303		3,781
Goodwill		15,742		16,000
Total assets	$	40,042	$	40,748

LIABILITIES AND EQUITY
Current liabilities:
Short-term debt	$	4,038	$	1,820
Sales reserves and allowances		3,955		4,143
Accounts payables		2,551		2,531
Employee-related obligations		588		739
Accrued expenses		2,962		2,687
Other current liabilities		1,036		1,182
Liabilities held for sale		296		354
Total current liabilities		15,425		13,456

Long-term liabilities:
Deferred income taxes		263		296
Other taxes and long-term liabilities		3,422		3,808
Senior notes and loans		12,680		14,986
Operating lease liabilities		266		288
Total long-term liabilities		16,632		19,379

Equity:
Teva shareholders' equity:		7,979		7,910
Non-controlling interests		5		4
Total equity		7,984		7,914
Total liabilities and equity	$	40,042	$	40,748

Amounts may not add up due to rounding.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(U.S. dollars in millions)
(Unaudited)

	Three months ended			Nine months ended
	September 30,			September 30,
		2026	2025		2026	2025
Operating activities:
Net income (loss)	$	234	434	$	27	937
Adjustments to reconcile net income (loss) to net cash provided by operations:
Depreciation and amortization		245	249		725	742
Impairment of long-lived assets and assets held for sale		228	79		350	255
Acquired in-process research and development*		23	17		785	52
Net change in operating assets and liabilities		(682)	(578)		(1,523)	(1,647)
Deferred income taxes ? net and uncertain tax positions		53	107		56	(76)
Stock-based compensation		38	34		121	106
Loss on extinguishment of debt		224	-		224	-
Other items		(53)	27		(65)	122
Net loss (gain) from sale of business and long-lived assets		(69)	-		(89)	-
Net cash provided by (used in) operating activities		241	369		612	491

Investing activities:
Beneficial interest collected in exchange for securitized accounts receivables		327	274		992	932
Purchases of property, plant and equipment and intangible assets		(120)	(136)		(393)	(359)
Proceeds from sale of businesses and long-lived assets, net		47	8		93	34
Purchases of in-process research and development*		(46)	(12)		(747)	(41)
Other investing activities		2	1		3	6
Net cash provided by (used in) investing activities		210	135		(52)	572

Financing activities:
Repayment of senior notes and loans and other long-term liabilities		(4,883)	(444)		(4,906)	(4,112)
Proceeds from senior notes, net of issuance costs		4,845	(7)		4,845	2,298
Purchase of shares from redeemable and non-redeemable non-controlling interests		-	-		-	(38)
Dividends paid to redeemable and non-redeemable non-controlling interests		-	-		-	(340)
Other financing activities		43	(2)		78	1
Net cash provided by (used in) financing activities		6	(453)		18	(2,191)

Effect of exchange rate changes on cash and cash equivalents		(27)	(9)		(49)	31

Net change in cash and cash equivalents		430	42		529	(1,097)
Balance of cash and cash equivalents at beginning of period		3,655	2,161	$	3,556	3,300

Balance of cash and cash equivalents at end of period	$	4,085	2,203	$	4,085	2,203

Non-cash financing and investing activities:
Beneficial interest obtained in exchange for securitized accounts receivables	$	253	296	$	859	937
Receivable for sale of long-lived assets		90	-		90	-

* In the first nine months of 2026, mainly related to the acquisition of Emalex and its primary asset ecopipam (EBS-101).

Amounts may not add up due to rounding.
The accompanying notes are an integral part of the financial statements.

Reconciliation of net income (loss) attributable to Teva
to Non-GAAP net income (loss) attributable to Teva
(Unaudited)
			Three months ended			Nine months ended
			September 30,			September 30,
	($ in millions except per share amounts)		2026	2025		2026	2025
	Net income (Loss) attributable to Teva	$	233	433	$	26	930
	Increase (decrease) for excluded items:
	Amortization of purchased intangible assets		139	144		415	436
	Legal settlements and loss contingencies(1)		201	60		503	309
	Impairment of long-lived assets(2)		228	79		350	255
	Restructuring costs(3)		58	29		121	196
	Equity compensation		38	34		121	106
	Contingent consideration		2	16		25	46
	Financial expenses(4)		235	7		256	58
	Other non-GAAP items(5)		14	51		55	170
	Corresponding tax effects and unusual tax items(6)		(134)	58		(216)	(225)
	Non-GAAP net income attributable to Teva	$	1,013	910	$	1,655	2,281
	Non-GAAP tax rate(7)		16.5 %	14.7 %		22.1 %	16.0 %
	GAAP diluted earnings (loss) per share attributable to Teva	$	0.20	0.37	$	0.02	0.80
	EPS difference(8)		0.66	0.41		1.38	1.16
	Non-GAAP diluted EPS attributable to Teva(8)	$	0.86	0.78	$	1.40	1.97
	Non-GAAP average number of shares (in millions)(8)		1,183	1,164		1,180	1,160

(1)	For the three months ended September 30, 2026, adjustments for legal settlements and loss contingencies mainly consisted of (a) an update to the estimated provision recorded in connection with one of the Company's ongoing antitrust litigations in the amount of $133 million, and (b) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $35 million. For the nine months ended September 30, 2026, adjustments for legal settlements and loss contingencies mainly consisted of (a) an estimated provision recorded in connection with one of the Company's ongoing antitrust litigations in the amount of $250 million, and (b) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $132 million. For the three and nine months ended September 30, 2025, adjustments of legal settlements and loss contingencies mainly consisted of (a) an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments) in the amount of $42 million and $139 million, respectively, and (b) an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the U.S. in the generic drug antitrust litigation in the amount of $55 million.
(2)	The expense for the three and nine months ended September 30, 2026, mainly consisted of (a) impairment charges in connection with several manufacturing facilities in Europe in the amount of $140 million and $210 million, respectively, and (b) impairment charges in connection with the held for sale measurement of the API business (including its R&D, manufacturing and commercial activities), which includes an impact related to the expected gain from reclassification of currency translation adjustments in the amount of $49 million and $66 million, respectively. For the nine months ended September 30, 2025, the adjustment for impairment of long-lived assets was mainly related to intangible assets in the U.S. and Europe.
(3)	In the nine months ended September 30, 2026 and 2025, Teva recorded restructuring expenses of $121 million and $196 million, respectively, primarily related to optimization activities in connection with Teva's Transformation programs related to Teva's global organization and operations mainly through headcount reduction.
(4)	In the three and nine months ended September 30, 2026, Teva recorded $224 million of finance expenses related to a loss on extinguishment of debt.
(5)	Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to material litigation fees, rationalization of our plants, accelerated depreciation and other unusual events.
(6)	Adjustments for corresponding tax effects and unusual tax items exclusively consisted of the tax impact directly attributable to the pre-tax items that are excluded from non-GAAP net income included in the other adjustments to this table.
(7)	Non-GAAP tax rate is tax expenses (benefit) excluding the impact of non-GAAP tax adjustments presented above as a percentage of income (loss) before income taxes excluding the impact of non-GAAP adjustments presented above. Our non-GAAP tax rate in the nine months ended September 30, 2026 was mainly affected by an unfavorable tax impact of a non-deductible acquired IPR&D charge related to the acquisition of Emalex and its primary asset ecopipam (EBS-101), the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, and other infrequent or non-recurring items, such as internal legal entities reorganization.
(8)	EPS difference and diluted non-GAAP EPS are calculated by dividing our non-GAAP net income attributable to Teva by our non-GAAP diluted weighted average number of shares.

Reconciliation of gross profit to Non-GAAP gross profit
(Unaudited)
		Three months ended			Nine months ended
		September 30,			September 30,
($ in millions)		2026	2025		2026	2025
Gross profit	$	2,440	2,304	$	6,565	6,282
Gross profit margin		55.5%	51.4%		52.4%	50.1%
Increase (decrease) for excluded items: (1)
Amortization of purchased intangible assets		129	134		387	406
Equity compensation		6	6		18	17
Other non-GAAP items		5	32		11	101
Non-GAAP gross profit	$	2,580	2,475	$	6,981	6,807
Non-GAAP gross profit margin (2)		58.7%	55.3%		55.8%	54.3%

(1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.
(2) Non-GAAP gross profit margin is non-GAAP gross profit as a percentage of revenue.

Reconciliation of operating income (loss) to Non-GAAP operating income (loss)
(Unaudited)

		Three months ended			Nine months ended
		September 30,			September 30,
($ in millions)		2026	2025		2026	2025
Operating income (loss)	$	714	882	$	1,135	1,857
Operating margin		16.2 %	19.7 %		9.1 %	14.8 %
Increase (decrease) for excluded items: (1)
Amortization of purchased intangible assets		139	144		415	436
Legal settlements and loss contingencies		201	60		503	309
Impairment of long-lived assets		228	79		350	255
Restructuring costs		58	29		121	196
Equity compensation		38	34		121	106
Contingent consideration		2	16		25	46
Loss (gain) on sale of business		(1)	6		(5)	19
Other non-GAAP items		15	45		60	149
Non-GAAP operating income (loss)	$	1,393	1,294	$	2,724	3,373
Non-GAAP operating margin(2)		31.7 %	28.9 %		21.8 %	26.9 %

(1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.
(2) Non-GAAP operating margin is Non-GAAP operating income as a percentage of revenues.

Reconciliation of net income (loss) to adjusted EBITDA
(Unaudited)
			Three months ended			Nine months ended
			September 30,			September 30,
($ in millions)			2026	2025		2026	2025
Net income (loss)		$	234	434	$	27	937
Increase (decrease) for excluded items:(1)
	Financial expenses		414	237		854	714
	Income taxes		66	214		254	210
	Share in profits (losses) of associated companies ?net		?	(2)		?	(4)
	Depreciation		106	105		311	306
	Amortization		139	144		415	436
EBITDA			959	1,131		1,861	2,599
	Legal settlements and loss contingencies		201	60		503	309
	Impairment of long lived assets		228	79		350	255
	Restructuring costs		58	29		121	196
	Equity compensation		38	34		121	106
	Contingent consideration		2	16		25	46
	Loss (Gain) on sale of Business		(1)	6		(5)	19
	Other non-GAAP items		12	40		50	137
Adjusted EBITDA		$	1,496	1,394	$	3,025	3,668

(1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table.
? Represents an amount of less than $0.5 million.

Segment Information
(Unaudited)

	United States					Europe						International Markets
	Three months ended September 30,					Three months ended September 30,						Three months ended September 30,
	2026		2025			2026			2025			2026			2025

	(U.S. $ in millions)					(U.S. $ in millions)						(U.S. $ in millions)

Revenues	$	1,870		$	2,090		$	1,319		$	1,235		$	592		$	557
Cost of sales	467			645			562			570			276			280
Gross profit	1,403			1,446			757			665			316			278
R&D expenses	196			161			62			62			31			26
S&M expenses	306			248			211			225			125			122
G&A expenses	109			113			64			75			34			36
Other	?			(3)			?			?			?			?
Segment profit*	$	791		$	927		$	420		$	303		$	125		$	95

* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million.

Segment Information
Unaudited

	United States				Europe				International Markets
	Nine months ended September 30,				Nine months ended September 30,				Nine months ended September 30,
	2026		2025		2026		2025		2026		2025

	(U.S. $ in millions)				(U.S. $ in millions)				(U.S. $ in millions)

Revenues	$	5,106	$	5,413	$	3,922	$	3,726	$	1,666	$	1,634
Cost of sales		1,462		1,742		1,727		1,687		823		835
Gross profit		3,644		3,670		2,195		2,039		843		799
R&D expenses		1,226		467		159		181		80		75
S&M expenses		898		741		648		652		370		353
G&A expenses		307		319		203		210		111		107
Other income		(9)		(1)		(3)		?		(8)		(3)
Segment profit	$	1,222	$	2,143	$	1,188	$	996	$	289	$	266

* Segment profit does not include amortization and certain other items.
? Represents an amount less than $0.5 million.

Reconciliation of our segment profit
to consolidated income (loss) before income taxes
	Three months ended
	September 30,
		2026		2025
	(U.S.$ in millions)

United States profit	$	791	$	927
Europe profit		420		303
International Markets profit		125		95
Total reportable segment profit		1,336		1,325
Profit (loss) of other activities		57		(31)
Amounts not allocated to segments:
Amortization		139		144
Other asset impairments, restructuring and other items		264		62
Intangible asset impairments		24		64
Legal settlements and loss contingencies		201		60
Other unallocated amounts		51		82
Consolidated operating income (loss)		714		882
Financial expenses - net		414		237
Consolidated income (loss) before income taxes	$	300	$	646

Reconciliation of our segment profit
to consolidated income (loss) before income taxes
	Nine months ended September 30,
	September 30,
	2026		2025
	(U.S.$ in millions)

United States profit	$	1,222	$	2,143
Europe profit		1,188		996
International Markets profit		289		266
Total reportable segment profit		2,699		3,405
Profit (loss) of other activities		25		(32)
Amounts not allocated to segments:
Amortization		415		436
Other asset impairments, restructuring and other items		438		272
Intangible asset impairments		54		227
Legal settlements and loss contingencies		503		309
Other unallocated amounts		179		272
Consolidated operating income (loss)		1,135		1,857
Financial expenses - net		854		714
Consolidated income (loss) before income taxes	$	282	$	1,143

Segment revenues by major products and activities
(Unaudited)

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)
United States segment
Generic products (including biosimilars)	$	718	$	1,175	(39)%
AJOVY		138		73	88 %
AUSTEDO		727		601	21 %
BENDEKA and TREANDA		30		35	(15)%
COPAXONE		58		62	(8)%
UZEDY		85		43	96 %
Other		114		101	13 %
Total		1,870		2,090	(11)%


	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)
Europe segment
Generic products (including OTC and biosimilars)	$	1,033	$	982	5 %
AJOVY		84		66	28 %
COPAXONE		38		44	(12)%
Respiratory products		54		52	3 %
Other*		111		91	21 %
Total		1,319		1,235	7 %

*Other revenues in the third quarter of 2026 and 2025 include the sale of certain product rights

	Three months ended				Percentage
	September 30,				Change
	2026		2025		2026-2025
	(U.S.$ in millions)
International Markets segment
Generic products (including OTC and biosimilars)	$	407	$	421	(3)%
AJOVY		48		30	61 %
AUSTEDO		24		17	42 %
COPAXONE		8		8	8 %
Other*		105		82	28 %
Total		592		557	6 %

*Other revenues in the third quarter of 2026 and 2025 include the sale of certain product rights

Segment revenues by major products and activities
(Unaudited)

	Nine months ended
	September 30,				Percentage Change
	2026		2025		2025-2026
	(U.S.$ in millions)
United States segment
Generic products	$	1,990	$	2,984	(33)%
AJOVY		341		190	80 %
AUSTEDO		1,963		1,492	32 %
BENDEKA / TREANDA		85		111	(24)%
COPAXONE		182		179	2 %
UZEDY		225		136	65 %
Other		321		321	?
Total		5,106		5,413	(6)%

? Represents an amount less than 0.5%.

	Nine months ended
	September 30,				Percentage Change
	2026		2025		2025-2026
	(U.S.$ in millions)
Europe segment
Generic products	$	3,146	$	3,011	4 %
AJOVY		238		195	22 %
COPAXONE		127		135	(6)%
Respiratory products		171		162	6 %
Other*		241		223	8 %
Total		3,922		3,726	5 %

*Other revenues in the first nine months of 2026 and 2025 include the sale of certain product rights.

	Nine months ended
	September 30,				Percentage Change
	2026		2025		2025-2026
	(U.S.$ in millions)
International Markets segment
Generic products	$	1,212	$	1,298	(7)%
AJOVY		130		78	68 %
AUSTEDO		63		34	82 %
COPAXONE		22		25	(13)%
Other*		239		199	20 %
Total		1,666		1,634	2 %

*Other revenues in the first nine months of 2026 and 2025 include the sale of certain product rights.

Free cash flow reconciliation
(Unaudited)

		Three months ended September 30,
		2026		2025
	(U.S. $ in millions)

Net cash provided by (used in) operating activities		241		369
Beneficial interest collected in exchange for securitized account receivables		327		274
Capital investment		(120)		(136)
Proceeds from sale of businesses and long-lived assets, net		47		8
Free cash flow	$	495	$	515

Free cash flow reconciliation
(Unaudited)

	Nine months ended September 30,
	2026		2025

	(U.S. $ in millions)

Net cash provided by (used in) operating activities		612		491
Beneficial interest collected in exchange for securitized trade receivables		992		932
Capital investment		(393)		(359)
Proceeds from sale of businesses and long-lived assets, net		93		34
Free cash flow	$	1,305	$	1,098

Net debt reconciliation
unaudited

		September 30,
	2026
Short-term debt		4,038
Senior notes and loans		12,680
Total debt		16,718
Net of cash and cash equivalents		4,085
Net debt	$	12,633

Seyond Expands Smart City Solution with LiDAR-Powered Operational Twin Capabilities and Technology Collaborations

Tue, 03 Nov 2026 22:22:00 +0700

Combining comprehensive LiDAR sensing, agentic AI-powered analytics, and technology collaborations to advance smart cities, critical infrastructure and safe spaces.

SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Seyond, a global provider of high-performance LiDAR solutions, is expanding its smart city and smart spaces solutions through advanced 3D sensing and technology collaborations.

By connecting spatial data with agentic AI-powered analytics and computing platforms, Seyond helps organizations improve safety, transportation, and infrastructure operations.

Growing Demand for Smart Cities and Intelligent Infrastructure

Smart cities are becoming an operational priority as organizations seek real-time intelligence to improve safety, transportation and operational efficiency. According to LP Information, the global smart-city LiDAR market was valued at approximately $358 million in 2025, with a projected compound annual growth rate of 18.7%, suggesting a market of approximately $425 million in 2026.

Demand for spatial intelligence now extends beyond roadways to airports, stadiums, utilities, data centers, and other critical infrastructures. These applications create opportunities to better understand movement, optimize space utilization, and improve operations.

Based on industry research and internal assumptions, Seyond estimates an illustrative annual serviceable addressable market of $1.3 billion to $2.0 billion in 2026 for expanded stationary LiDAR applications outside China. This sensor-focused estimate represents potential market opportunity, not projected company revenue.

Seyond: Enabling Spatial Intelligence Across Smart Environments

Seyond's comprehensive LiDAR portfolio, spanning ultra-long-range to short-range sensing, supports applications from transportation infrastructure to localized indoor and outdoor environments. Its technology generates high-resolution 3D spatial data to measure vehicle movement, pedestrian flows, and environmental activity without relying on identifiable photographic imagery, providing a privacy-conscious foundation for spatial analytics.

These capabilities support continuous spatial awareness across intersections, transportation hubs, commercial facilities, and public gathering spaces. Combined with AI-powered analytics and computing platforms, Seyond's sensing technology helps organizations translate physical-world data into actionable insights, enabling more responsive infrastructure and better-informed operational decisions.

Expanding Technology Collaborations to Deliver Complete Operational Twin Solutions

Delivering practical smart city solutions increasingly requires collaboration across sensing, computing, AI, and software. One example is the digital operational twins, dynamic digital representation of a physical environment that reflects activity and movement in real time, helping operators understand changing conditions and make informed decisions.

At Smart City Expo World Congress 2026, November 3-5 in Barcelona, Seyond will participate as an exhibition partner at the Dell Technologies booth, showcasing a live LiDAR-powered operational twin.

By combining Seyond's sensing capabilities with technologies from Dell and NVIDIA, the demonstration will illustrate how integrated solutions can support pedestrian-flow analysis, space utilization, and real-time operational awareness. The solution will feature a Dell Technologies system powered by the NVIDIA DGX Spark, which combines a 20-core Arm Grace CPU with an NVIDIA Blackwell GPU.

Fused data from LiDAR, video, and other sensors feeds a live operational twin, giving operators a unified view of activity across the environment. The solution integrates vision AI agents built with NVIDIA Metropolis Blueprint for video search and summarization (VSS) and NVIDIA Cosmos to enhance scene understanding and support informed operational decisions.

Seyond is also collaborating with AMSYS to advance integrated spatial intelligence solutions for large-scale venues and public environments. Combining Seyond's LiDAR sensing with the AMSYS Fusion Core Perception Platform, these solutions are designed to translate anonymous movement and occupancy data into actionable operational insights.

In a stadium or major event venue, for example, this approach could help operators monitor crowd density, analyze queues, and identify congestion across entrances and gathering areas. These insights could support better decisions about staffing, crowd movement, and resource allocation while maintaining a privacy-conscious approach to sensing.

Together, these collaborations demonstrate Seyond's expanding role in connecting advanced sensing with AI, computing, and operational software. As investment in intelligent infrastructure grows, Seyond remains focused on bringing practical spatial intelligence solutions to cities, critical infrastructure and safe spaces.

About Seyond

Seyond is a global provider of high-performance LiDAR solutions for automotive, robotics, intelligent transportation, smart infrastructure, and other applications. Its comprehensive portfolio of advanced 3D sensing technologies enables accurate, reliable spatial intelligence across a wide range of environments.

Hopscotch launches Hopscotch Public Engagement, a new entity dedicated to the European institutions

Tue, 03 Nov 2026 22:19:00 +0700

Press release

Paris, November 3rd 2026 --

Hopscotch launches Hopscotch Public Engagement, a new entity dedicated to the European institutions

The communications Group is combining its integrated expertise and international network to support the EU institutions meet their communication challenges and the demands of major public contracts.

HOPSCOTCH, the international communications Group founded in France, today announces the launch of Hopscotch Public Engagement. The new Brussels-based entity will primarily serve the EU institutions and, more broadly, the European public sector.

The launch reflects the Group's ambition to strengthen its presence with the EU institutions. Much of their communication work is commissioned through multi-year framework contracts spanning several areas of expertise and several countries. Hopscotch Public Engagement will meet these needs by drawing on the strengths of an integrated communications group: specialist expertise, sector knowledge and the ability to deliver across Europe.

An integrated offer built for the challenges of public communication

From 360? communication campaigns to events, digital, influence and public relations, Hopscotch Public Engagement brings together the Group's expertise to design and deliver communication strategies suited to the complexity of EU issues. This integrated approach meets the wide range of the institutions'needs. It is also built for framework contracts, which are typically split into multiple lots and require several disciplines and teams to work in close coordination.

The entity builds on the experience HOPSCOTCH has developed with private- and public-sector clients, adapting it to the conventions and requirements of EU institutional communication. This includes the Group's approaches to Relational Capital and augmented public relations, which help institutions explain their work, strengthen dialogue with their audiences and deliver their messages at the right time.

The offer relies on the Group's sector expertise and international network. As an independent European group, HOPSCOTCH has more than 40 offices worldwide. Its organisation is designed to support pan-European campaigns and to coordinate communication programmes across European markets.

The Group also draws on the experience of its international network, formerly Sopexa, in supporting regulated sectors and European programmes for agriculture and food industry players. It also runs international campaigns on behalf of the European Commission's Directorate-General for Agriculture and Rural Development (DG AGRI) and the European Research Executive Agency (REA).

"The launch of Hopscotch Public Engagement reflects a conviction the Group holds firmly: the biggest communication challenges now play out at European level. With this new entity, we are combining in-depth knowledge of the institutions with our network's ability to coordinate programmes across European and international markets," says Sylvain Rouchy, Vice President, Global Operations at HOPSCOTCH.

Based in Brussels, Hopscotch Public Engagement works alongside Hopscotch Belgium, the Group's brand communication agency for the Belgian market, led by M?lanie Rouchy.

"Setting up Hopscotch Public Engagement in Brussels is a great opportunity to strengthen synergies within the Group and to put our complementary expertise at the service of the European institutions," says M?lanie Rouchy, Managing Director of Hopscotch Belgium.

A shared ambition to serve Europe

Hopscotch Public Engagement is co-led by Caroline Danloy and Nicolas Balland. Between them, they bring knowledge of the European institutions, communications expertise and experience in leading multidisciplinary teams.

Caroline Danloy has extensive experience in strategic communication for international and European institutional clients. Over a 25-year career, she has served as Vice President at ICF Next, where she led 360? communication teams delivering major European campaigns.

"We are at a turning point for European democracy. Communicating about the work of the European institutions and the challenges they face is more important than ever, and it is a mission I have been proud to carry out for 25 years," says Caroline Danloy, Co-Managing Director of Hopscotch Public Engagement.

"Hopscotch brings a rare combination to this market: the scale and maturity of an international network headquartered in France, expertise spanning the public and private sectors, and real depth of subject knowledge. Communicating for public institutions involves many topics and stakeholders, and this combination is exactly what that complexity demands. Alongside Nicolas, whose experience I know well, I look forward to putting these strengths at the service of the European institutions with Hopscotch Public Engagement."

Nicolas Balland brings more than 20 years of experience in the communications industry, particularly in events, public relations and institutional communication. After holding various roles at ICF Next, he joined Tipik, where he led Event, Studio and Audiovisual teams before becoming Managing Director.

"This is a project Caroline and I had been thinking about for several years. When we met Hopscotch, we quickly realised that we shared the same ambition," explains Nicolas Balland, Co-Managing Director of Hopscotch Public Engagement.

"Today, we are proud to offer the European institutions the strength of a leading communications Group, combined with distinctive expertise and in-depth knowledge of European issues. Our ambition goes beyond designing and delivering communication campaigns: we want to build an organisation that connects institutions, citizens and ideas, and that takes concrete action for Europe."

About HOPSCOTCH

HOPSCOTCH is an international communications Group founded in France, driven by an entrepreneurial vision and the complementary nature of its talents and expertise.

HOPSCOTCH is a unique combination of expertise, driven by the belief that the value of a company or organisation lies in the quality of its Relational Capital.

With more than 1,200 employees, half of whom are based internationally (40 offices across 5 continents), HOPSCOTCH covers all areas of communication: influence, events, public relations, activations, digital, internal communication, public affairs, and marketing services.

HOPSCOTCH organises its agencies around its areas of expertise:

Event: Hopscotch Event, Hopscotch Congr?s, Hopscotch Moments, Sagarmatha.

Public Relations: Hopscotch PR, Le Public Syst?me PR, Human to Human, Hopscotch D?cideurs.

Digital and Marketing: heaven, AD Crew, Hopscotch Digital Studio, Sublime.

Media: Hopscotch Media

Sectorial expertise: Hopscotch Cin?ma, Hopscotch Luxe, Hopscotch Season, Hopscotch Sport, Hopscotch Tourism.

HOPSCOTCH has been committed to ambitious ecological and societal initiatives for over 15 years, validated by internationally recognized CSR certifications, including RSE Agences Actives, ISO 20121, and the EcoVadis Gold medal.

In 2026, HOPSCOTCH was named "Global Agency of the Year" by PRovoke Media.

Listed on Euronext Growth Paris (Ticker code: ALHOP FR ; ISIN code: FR 00000 6527 8), the Group represents a turnover of ?270,8 million and a gross margin of ?98,8 million in 2025.

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Tue, 03 Nov 2026 21:54:00 +0700

*Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO upon close and infliximab-abda in Q3 2027

*Collaboration combines Samsung Bioepis' biosimilar expertise with Teva's commercial capabilities

*Agreement expands collaboration with Samsung Bioepis, strengthening Teva's generics powerhouse and biosimilars portfolio as part of its Pivot to Growth strategy

TEL AVIV, Israel and INCHEON, South Korea, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that they have entered into a license and commercialization agreement for two FDA-approved immunology biosimilars: infliximab-abda, a biosimilar to Remicade 1 (infliximab) and ETICOVO (etanercept-ykro), a biosimilar to Enbrel 2 (etanercept).

Under the terms of the agreement, Teva will obtain U.S. commercialization rights to etanercept-ykro at closing, while U.S. commercialization rights to infliximab-abda will transfer to Teva in Q3 2027. The timing of Teva's future U.S. commercialization of etanercept-ykro will be announced at a later date. Samsung Bioepis will remain responsible for regulatory oversight and manufacturing of both products. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals, and is currently anticipated to close by the end of 2026.

"This agreement strengthens our collaboration with Samsung Bioepis and will expand our U.S. immunology portfolio with two additional biologic treatment options," said Richard Francis, President and CEO of Teva. "Biosimilars are an important part of our Pivot to Growth strategy, helping us build a stronger portfolio while expanding access to high-quality medicines. Together, we have an opportunity to bring more treatment choices to patients living with chronic inflammatory conditions."

"We are delighted to expand our strategic alliance with Teva to strengthen the commercial footprint of our immunology portfolio in the U.S.," said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. "Infliximab-abda has established a proven track record of clinical efficacy and supply reliability since its launch, while ETICOVO represents an FDA-approved therapy poised to broaden treatment choices for patients. By pairing our dedication to high-quality biologic development and manufacturing with Teva's commercial reach across U.S. healthcare channels, we aim to ensure uninterrupted treatment continuity for existing patients and bring sustainable value to the U.S. healthcare system."

Under the terms of the agreement and subject to certain conditions, Teva will pay Samsung Bioepis an upfront payment over the next 3 years. Samsung Bioepis may be eligible for additional launch and sales milestones payments. Teva and Samsung Bioepis will share profit from the commercialization of these products.

The agreement builds on a series of biosimilar collaborations between Teva and Samsung Bioepis. In 2025, the companies announced a U.S. agreement for EPYSQLI (eculizumab-aagh), a biosimilar to Soliris3 (eculizumab). In 2026, the companies announced two agreements, including one for OPUVIZ (aflibercept) in Canada and a separate global agreement to license, develop and commercialize up to six potential biosimilar candidates currently in early-stage development, including biosimilar candidates referencing Fasenra4 (benralizumab) and Ilaris5 (canakinumab).

About Infliximab-abda and etanercept-ykro

Both biosimilars are tumor necrosis factor (TNF) inhibitors indicated for the treatment of chronic inflammatory and autoimmune conditions:

infliximab-abda6 was approved by the FDA in 2017 for indications including Crohn's disease (adult and pediatric), ulcerative colitis (adult and pediatric), rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Teva will newly assume commercialization of the product, scheduled to take effect in the third quarter of 2027.

etanercept-ykro7 was approved by the FDA in 2019 and is not currently available on the U.S. market. It is approved for indications including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (patients aged 2 years and older), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis (patients aged 4 years and older).

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR INFLIXIMAB-ABDA

SERIOUS INFECTIONS

Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue infliximab-abda if a patient develops a serious infection or sepsis.

Reported infections include:

Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before infliximab-abda use and during therapy. Treatment for latent infection should be initiated prior to infliximab-abda use.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, pneumocystosis, and cryptococcosis. Patients may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella, Listeria, and Salmonella.

The risks and benefits of treatment with infliximab-abda should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with infliximab-abda, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy, who are on treatment for latent TB, or who were previously treated for TB infection.

Risk of infection may be higher in patients greater than 65 years of age, pediatric patients, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressant therapy. In clinical trials, other serious infections observed in patients treated with infliximab products included pneumonia, cellulitis, abscess, and skin ulceration.

MALIGNANCIES

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. Approximately half of these cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months after the first dose of therapy. Most of the patients were receiving concomitant immunosuppressants.

Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis and most were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treatment with infliximab-abda, especially in these patient types.

In clinical trials of all TNF inhibitors, more cases of lymphoma were observed compared with controls and the expected rate in the general population. However, patients with Crohn's disease, rheumatoid arthritis, or plaque psoriasis may be at higher risk for developing lymphoma. In clinical trials of some TNF inhibitors, including infliximab products, more cases of other malignancies were observed compared with controls. The rate of these malignancies among patients treated with infliximab products was similar to that expected in the general population whereas the rate in control patients was lower than expected. Cases of acute and chronic leukemia have been reported with postmarketing TNF-blocker use. As the potential role of TNF inhibitors in the development of malignancies is not known, caution should be exercised when considering treatment of patients with a current or a past history of malignancy or other risk factors such as chronic obstructive pulmonary disease (COPD).

Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-blocker therapy, including infliximab products. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.

A population-based retrospective cohort study found a 2- to 3-fold increase in the incidence of invasive cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics-na?ve patients or the general population, particularly those over 60 years of age. A causal relationship between infliximab products and cervical cancer cannot be excluded. Periodic screening should continue in women treated with infliximab products.

CONTRAINDICATIONS

The use of infliximab-abda at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure. infliximab-abda is contraindicated in patients with a previous severe hypersensitivity reaction to infliximab products or any of the inactive ingredients of infliximab-abda or any murine proteins (severe hypersensitivity reactions have included anaphylaxis, hypotension, and serum sickness).

WARNINGS AND PRECAUTIONS

HEPATITIS B REACTIVATION

TNF inhibitors, including infliximab products, have been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases were fatal. Patients should be tested for HBV infection before initiating INFLIXIMAB-ABDA. For patients who test positive, consult a physician with expertise in the treatment of hepatitis B. Exercise caution when prescribing infliximab-abda for patients identified as carriers of HBV and monitor closely for active HBV infection during and following termination of therapy with INFLIXIMAB-ABDA. Discontinue infliximab-abda in patients who develop HBV reactivation and initiate antiviral therapy with appropriate supportive treatment. Exercise caution when considering resumption of infliximab-abda and monitor patients closely.

HEPATOTOXICITY

Severe hepatic reactions, including acute liver failure, jaundice, hepatitis, and cholestasis have been reported rarely in patients receiving infliximab products postmarketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (eg, ≥5 times the upper limit of normal) develop, infliximab-abda should be discontinued, and a thorough investigation of the abnormality should be undertaken.

HEMATOLOGIC EVENTS

Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported in patients using infliximab products. The causal relationship to infliximab therapy remains unclear. Exercise caution in patients who have ongoing or a history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs and symptoms of blood dyscrasias or infection. Consider discontinuation of infliximab-abda in patients who develop significant hematologic abnormalities.

HYPERSENSITIVITY

Infliximab products have been associated with hypersensitivity reactions that differ in their time of onset and required hospitalization in some cases. Most hypersensitivity reactions (including anaphylaxis, urticaria, dyspnea, and/or hypotension) have occurred during or within 2 hours of infliximab product infusion. Serious infusion reactions including anaphylaxis were infrequent. infliximab-abda should be discontinued for severe hypersensitivity reactions. Medications for the treatment of hypersensitivity reactions should be available.

CARDIOVASCULAR AND CEREBROVASCULAR REACTIONS DURING AND AFTER INFUSION

Serious cerebrovascular accidents, myocardial ischemia/infarction (some fatal), hypotension, hypertension, and arrhythmias have been reported during and within 24 hours of initiation of infliximab infusion. Cases of transient visual loss have been reported during or within 2 hours of infusion of infliximab. Monitor patients during infusion and, if a serious reaction occurs, discontinue infusion. Manage reactions according to signs and symptoms.

NEUROLOGIC EVENTS

TNF inhibitors, including infliximab products, have been associated in rare cases with central nervous system (CNS) manifestation of systemic vasculitis, seizure, and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr? syndrome. Exercise caution when considering infliximab-abda in patients with these disorders and consider discontinuation if these disorders develop.

AUTOIMMUNITY

Treatment with infliximab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

DRUG INTERACTIONS

USE WITH OTHER DRUGS

Concurrent use of infliximab-abda with other biological products used to treat the same conditions as infliximab-abda is not recommended because of the possibility of an increased risk of infection. Care should be taken when switching from one biologic to another, since overlapping biological activity may further increase the risk of infection.

VACCINATIONS AND USE OF LIVE VACCINES/THERAPEUTIC INFECTIOUS AGENTS

Prior to initiating infliximab-abda in pediatric and adult patients, update vaccinations in accordance with current vaccination guidelines. Live vaccines or therapeutic infectious agents should not be given with infliximab-abda due to the possibility of clinical infections, including disseminated infections.

At least a 6-month waiting period following birth is recommended before the administration of any live vaccine to infants exposed in utero to infliximab products.

ADVERSE REACTIONS

In clinical trials, the most common adverse reactions occurring in >10% of patients included infections (e.g., upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain.

INDICATIONS

Infliximab-abda is a TNF blocker indicated for:

Crohn's Disease

Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy.

Infliximab-abda is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn's disease.

Pediatric Crohn's Disease

Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age or older with moderately to severely active Crohn's disease (CD) who have had an inadequate response to conventional therapy.

Ulcerative Colitis

Infliximab-abda is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

Pediatric Ulcerative Colitis

Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

Rheumatoid Arthritis

Infliximab-abda is indicated, in combination with methotrexate (MTX), for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA).

Ankylosing Spondylitis

Infliximab-abda is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS).

Psoriatic Arthritis

Infliximab-abda is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA).

Plaque Psoriasis

Infliximab-abda is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. Infliximab-abda should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Please read the Full Prescribing Information, including BOXED WARNINGS and Medication Guide.

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR ETICOVO (etanercept-ykro)

SERIOUS INFECTIONS

Patients treated with etanercept products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ETICOVO should not be initiated in the presence of sepsis, active infections, or allergy to ETICOVO or its components. ETICOVO should be discontinued if a patient develops a serious infection or sepsis.

Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before ETICOVO use and periodically during therapy. Initiate treatment for latent infection prior to ETICOVO use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with ETICOVO should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with ETICOVO, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.

MALIGNANCIES

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including etanercept products.

In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA patients. The role of TNF blocker therapy in the development of malignancies is unknown.

Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population.

Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including etanercept products. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.

Pediatric Patients

In patients who initiated therapy at ≤18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin's and non-Hodgkin's lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.

CONTRAINDICATIONS

ETICOVO is contraindicated in patients with sepsis.

WARNINGS AND PRECAUTIONS

NEUROLOGIC REACTIONS

Treatment with TNF-blocking agents, including etanercept products, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barr? syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ETICOVO therapy. Prescribers should exercise caution in considering the use of ETICOVO in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.

NEW ONSET OR WORSENING OF HEART FAILURE

Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking etanercept products. Caution should be used when using ETICOVO in patients with CHF. These patients should be carefully monitored.

HEMATOLOGIC REACTIONS

Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to etanercept products therapy remains unclear. Exercise caution when considering ETICOVO in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ETICOVO if significant hematologic abnormalities are confirmed.

HEPATITIS B REACTIVATION

Reactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including etanercept products. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ETICOVO in these patients.

ALLERGIC REACTIONS

Allergic reactions associated with administration of ETICOVO during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, discontinue administration of ETICOVO and initiate appropriate therapy immediately.

IMMUNIZATIONS

Avoid concurrent administration of live vaccines with ETICOVO. Patients, if possible, should be brought up to date with all immunizations prior to initiating ETICOVO. In patients with exposure to varicella virus, temporarily discontinue ETICOVO and consider prophylactic treatment with Varicella Zoster Immune Globulin.

AUTOIMMUNITY

Autoantibodies may develop with ETICOVO, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ETICOVO. Stop ETICOVO if findings suggestive of lupus-like syndrome or autoimmune hepatitis develop and evaluate the patient.

NOT RECOMMENDED FOR GRANULOMATOSIS WITH POLYANGIITIS PATIENTS ON IMMUNOSUPPRESSANTS

The use of ETICOVO in patients with granulomatosis with polyangiitis receiving immunosuppressive agents (e.g., cyclophosphamide) is not recommended.

INCREASED MORTALITY IN PATIENTS WITH MODERATE TO SEVERE ALCOHOLIC HEPATITIS

Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ETICOVO in patients with moderate to severe alcoholic hepatitis.

DRUG INTERACTIONS

The use of ETICOVO in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ETICOVO and anakinra is not recommended. Hypoglycemia has been reported following initiation of ETICOVO therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.

ADVERSE REACTIONS

The most commonly reported adverse reactions in RA clinical trials were injection site reaction and infection. In clinical trials of all other adult indications, adverse reactions were similar to those reported in RA clinical trials.

In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population.

INDICATIONS

ETICOVO (etanercept-ykro) is a TNF blocker indicated for:

Rheumatoid Arthritis: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA).

Polyarticular Juvenile Idiopathic Arthritis (pJIA): Reducing signs and symptoms of moderately to severely active pJIA in patients 2 years of age and older.

Psoriatic Arthritis: Reducing signs and symptoms, inhibiting structural damage progression, and improving physical function in adults (alone or with methotrexate).

Ankylosing Spondylitis: Reducing signs and symptoms in patients with active disease.

Plaque Psoriasis: Treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Please read the Full Prescribing Information, including BOXED WARNINGS and Medication Guide.

About Teva

Teva Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "project," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute the agreement with Samsung Bioepis and to successfully commercialize infliximab-abda and ETICOVO (etanercept-ykro) in the U.S.; our ability to successfully execute our additional collaborations with Samsung Bioepis; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and other factors discussed in our Quarterly Reports on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ending December 31, 2025, including in the section captioned "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings (KRX: 0126Z0), Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

_______________

1 Remicade is a trademark of Janssen Biotech, Inc., a Johnson & Johnson company

2 Enbrel is a trademark of Immunex Corporation, an Amgen subsidiary.

3 Soliris is a trademark of Alexion Pharmaceuticals, Inc.

4 Fasenra is a trademark of AstraZeneca AB.

5 Ilaris is a trademark of Novartis AG.

6 infliximab-abda - FDA-approved biosimilar to Remicade (infliximab): https://purplebooksearch.fda.gov/index.cfm?event=productdetails&blaNo=761054

7 etanercept-ykro - FDA-approved biosimilar to Enbrel (etanercept): https://purplebooksearch.fda.gov/index.cfm?event=productdetails&blaNo=761066

Bridge Data Centres Appoints New Co-Chief Executive Officer

Tue, 03 Nov 2026 21:45:00 +0700

Source: Bridge Data Centres

Mr Drew Chen's appointment as Co-CEO strengthens BDC's leadership team as the Company surpasses one gigawatt of capacity in 2026 and accelerates its growth across Asia Pacific.

SINGAPORE - Media OutReach Newswire - 3 November 2026 - Bridge Data Centres (BDC) is pleased to announce the appointment of Mr Drew Chen as Co-Chief Executive Officer (Co-CEO), effective 1 November 2026. He will work alongside Mr Eric Fan, BDC's Co-CEO, as a key member of the leadership team to accelerate the Company's growth across Asia Pacific and beyond.

Mr Chen brings over 20 years of private equity experience, with a focus on the telecommunications, media, technology, and business services sectors. He previously served as a Senior Partner at Bain Capital and was a founding member of the firm's Asia Pacific private equity team.

Prior to Bain Capital, Mr Chen worked at Bain & Company. He holds a bachelor's degree in economics from Harvard University and an MBA from Harvard Business School.

Mr Eric Fan, Co-CEO of Bridge Data Centres, said, "On behalf of Bridge Data Centres, we would like to welcome Drew. His appointment strengthens our leadership team at an important point in BDC's growth, as we surpass one gigawatt of capacity in 2026. Drew's experience and deep domain knowledge of the data centre sector will support our strategy as we scale BDC into a multi-gigawatt digital infrastructure platform in the coming years."

Mr Drew Chen, Co-CEO of Bridge Data Centres, said, "The Asia Pacific data centre sector is at inflection point for growth, fuelled by surging cloud adoption and the rapid expansion of AI workloads. BDC is well positioned to capture this opportunity, backed by our world class engineering and design team, longstanding partnerships with global clients, and a decade of experience developing and operating next-generation digital infrastructure. I am excited to partner with Eric and the leadership team to scale BDC's footprint across Asia Pacific and support our customers' ambitious growth plans."

Mr Jonathan Zhu, Partner and Chair of China at Bain Capital, said, "Drew possesses deep expertise in the digital infrastructure space and an intimate knowledge of BDC's business, having played a pivotal role in the buildout of BDC and its sister company ChinData. We are delighted that, as the Co-CEO, Drew will continue to bring strategic foresight and robust business building capabilities to BDC. Together, he and Eric are well positioned to lead BDC through its next chapter of growth."

Headquartered in Singapore, BDC is one of Asia Pacific's top three next-generation digital infrastructure platforms by live capacity, with a presence across Malaysia, Thailand, Singapore, and India.

About Bridge Data Centres

Bridge Data Centres (BDC) is a Singapore headquartered digital infrastructure platform delivering next-generation data centres across Asia Pacific and beyond.

Backed by Bain Capital, BDC operates in Malaysia, Thailand, India, and other high-growth markets, with an ambition to scale into a multi-gigawatt digital infrastructure platform in the near future.

The issuer is solely responsible for the content of this announcement.

Hashtags: #BridgeDataCentres

https://www.bridgedatacentres.com/

https://th.linkedin.com/company/bridgedc

YYForce Menyoroti Aset Bersih yang Dilaporkan Sebesar US$21,9 Juta serta Menguraikan Prioritas Robotika Komersial dan Platform AI

Tue, 03 Nov 2026 21:31:00 +0700

YYForce menyajikan nilai buku ekuitas yang telah dilaporkan beserta kapitalisasi pasarnya untuk memberikan konteks tambahan terkait rencana pertumbuhan perusahaan kepada rencana pertumbuhan perusahaan

SINGAPURA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- YYForce Inc. (Nasdaq: YFOR) ("YYForce" atau "Perusahaan"), penyedia solusi tenaga kerja dan layanan pengelolaan fasilitas terpadu berbasis teknologi, hari ini menyoroti aset bersih perusahaan yang dilaporkan sebesar sekitar US$21,9 juta, dibandingkan dengan estimasi kapitalisasi pasar sekitar US$2,1 juta per 30 Oktober 2026, serta menguraikan prioritas perusahaan di bidang robotika komersial dan AI.

YYForce menyampaikan informasi ini untuk membantu investor mengevaluasi basis aset yang dilaporkan perusahaan beserta hasil operasional, likuiditas, serta strateginya di bidang platform tenaga kerja, pengelolaan fasilitas terpadu, dan robotika layanan.

Posisi keuangan yang dilaporkan dan perbandingan valuasi

Sebagaimana dilaporkan dalam Formulir 6-K Perusahaan yang telah disampaikan pada 25 September 2026, neraca konsolidasian YYForce per 30 Juni 2026 menunjukkan angka-angka berikut.

Pos neraca	Jumlah yang dilaporkan
Total aset	Sekitar US$38 juta
Ekuitas yang dapat diatribusikan kepada pemegang saham YYForce (aset bersih)	Sekitar US$21,9 juta

Per 30 Oktober 2026, estimasi kapitalisasi pasar ekuitas perusahaan mencapai sekitar US$2,1 juta, setara dengan sekitar 9,6% dari ekuitas yang dilaporkan dan dapat diatribusikan kepada pemegang saham YYForce. Angka tersebut menunjukkan diskon sekitar 90,4% terhadap nilai buku ekuitas yang dilaporkan. Informasi ini menggunakan angka yang telah dibulatkan serta mencerminkan data keuangan dan data pasar dari tanggal yang berbeda.

Nilai buku ekuitas tidak mencerminkan kas yang penggunaannya tidak dibatasi, aset bersih berwujud, hasil likuidasi, atau estimasi nilai intrinsik. Nilai tercatat aset bergantung pada estimasi akuntansi dan penilaian penurunan nilai. Investor perlu mempertimbangkan laporan keuangan secara keseluruhan, termasuk liabilitas, hasil operasional, arus kas, dan pengungkapan selanjutnya.

Komentar manajemen

"Kami meyakini bahwa selisih antara nilai buku ekuitas yang kami laporkan dan kapitalisasi pasar perusahaan di pasar publik patut mendapat perhatian investor," ujar Mike Fu, Chief Executive Officer YYForce. "Tanggung jawab kami adalah menyediakan informasi keuangan yang jelas dan melaksanakan strategi komersial kami. Kami tetap berfokus pada penyediaan layanan bagi pelanggan, alokasi modal yang disiplin, serta pengembangan bisnis solusi tenaga kerja, pengelolaan fasilitas, dan robotika layanan kami."

"Kami akan mengevaluasi setiap investasi berdasarkan permintaan pelanggan, likuiditas yang tersedia, kebutuhan modal, dan imbal hasil yang diharapkan," tambah Fu.

Prioritas pertumbuhan strategis

Ekspansi robotika komersial. Mengupayakan penerapan robotika layanan dan integrasinya ke dalam alur kerja sektor perhotelan dan perusahaan, dengan memperhatikan kebutuhan pelanggan, biaya penerapan, serta dukungan berkelanjutan.

Platform pengelolaan fasilitas dan tenaga kerja yang didukung AI. Mengembangkan kemampuan platform digital dan mendorong penerapannya di perusahaan untuk mendukung koordinasi tenaga kerja, pelaksanaan shift kerja, dan operasional fasilitas.

Disiplin pengelolaan modal dan transparansi pasar. Mengevaluasi penerapan komersial berdasarkan permintaan pelanggan, kebutuhan modal, dan imbal hasil yang diharapkan. Selain itu, memberikan informasi terbaru yang jelas kepada pemegang saham mengenai perkembangan yang signifikan.

YYForce akan terus menilai kinerja operasional, kebutuhan pembiayaan, dan prioritas alokasi modalnya sesuai dengan perkembangan bisnisnya. Kemajuan komersial di masa mendatang tetap bergantung pada pelaksanaan operasional, tingkat adopsi oleh pelanggan, dan kondisi pasar yang lebih luas.

Tentang YYForce Inc.

YYForce Inc. (Nasdaq: YFOR) adalah perusahaan penyedia solusi tenaga kerja dan layanan pengelolaan fasilitas terpadu berbasis teknologi. Perusahaan tengah mengembangkan platform pengelolaan tenaga kerja dan kapabilitas robotika berteknologi AI untuk mendukung kegiatan operasional di lini depan, meningkatkan produktivitas, serta memenuhi kebutuhan pelanggan yang terus berkembang.

Untuk informasi lebih lanjut, kunjungi www.yyforce.ai.

Pernyataan Berwawasan ke Depan

Siaran pers ini memuat pernyataan berwawasan ke depan sebagaimana dimaksud dalam Pasal 27A Undang-Undang Sekuritas AS Tahun 1933, sebagaimana telah diubah, dan Pasal 21E Undang-Undang Perdagangan Sekuritas AS Tahun 1934, sebagaimana telah diubah. Pernyataan-pernyataan tersebut didasarkan pada ekspektasi dan asumsi Perusahaan saat ini, serta informasi yang tersedia bagi Perusahaan pada tanggal rilis siaran pers ini. Pernyataan berwawasan ke depan dapat dikenali melalui penggunaan kata-kata seperti "mungkin", "akan", "seharusnya", "memperkirakan", "mengantisipasi", "merencanakan", "bermaksud", "meyakini", "mengestimasi", "potensi", atau ungkapan serupa, maupun bentuk negatif dari istilah-istilah tersebut.

Pernyataan berwawasan ke depan dalam siaran pers ini termasuk, tetapi tidak terbatas pada, ekspektasi mengenai strategi, penerapan komersial, pengembangan platform, efisiensi operasional, alokasi modal, dan kinerja bisnis Perusahaan di masa mendatang. Data keuangan historis bukan merupakan pernyataan berwawasan ke depan. Nilai buku ekuitas yang dilaporkan bukan merupakan indikator harga yang mungkin berlaku dalam perdagangan saham perusahaan maupun jumlah yang mungkin diperoleh dari penjualan atau likuidasi.

Pernyataan berwawasan ke depan mengandung risiko dan ketidakpastian yang melekat, dan peristiwa di masa mendatang yang dibahas dalam siaran pers ini mungkin tidak terjadi. Peristiwa dan hasil aktual dapat berbeda secara signifikan serta bergantung pada risiko, ketidakpastian, asumsi mengenai Perusahaan, dan sejumlah faktor lainnya.

Untuk pembahasan lebih terperinci mengenai faktor-faktor risiko, silakan merujuk pada dokumen yang diserahkan Perusahaan kepada Komisi Sekuritas dan Bursa AS (SEC), termasuk bagian "Faktor Risiko" dalam laporan tahunan terbaru Perusahaan pada Formulir 20-F, sebagaimana diubah. YYForce tidak berkewajiban untuk memperbarui pernyataan ini kecuali sebagaimana diwajibkan oleh hukum yang berlaku.

Berakar pada Perpetua, EXEED Memperkenalkan Bahasa Desain Barunya: Kemewahan Masa Depan

Tue, 03 Nov 2026 21:28:00 +0700

SHANGHAI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Acara "Peluncuran Bahasa Desain Baru" berlangsung di Pusat Inovasi Teknologi Global Chery di Shanghai sebagai bagian dari EXEED International User Summit 2026. Mengusung tema "Kemewahan Masa Depan", acara tersebut memperkenalkan bahasa desain baru untuk seluruh lini kendaraan EXEED.

Penata Desain Merek, Christo Pavlidis, dan Kepala Desainer, Juan Manuel Diaz, memperkenalkan lima model kendaraan, yaitu ES GT, EX9, EX8, EX7, dan MPV Concept. Kelima model tersebut masing-masing menghadirkan interpretasi tersendiri atas konsep Kemewahan Masa Depan. Setiap model memenuhi ekspektasi pengguna yang terus berkembang terhadap kemewahan, performa, dan teknologi mutakhir.

Inti dari konsep Kemewahan Masa Depan adalah Perpetua, sebuah filosofi desain yang terinspirasi dari perubahan gelombang Samudra Atlantik mengikuti cahaya, pasang surut air laut, dan waktu. Filosofi ini diwujudkan dalam dua bentuk ekspresi. Air berwujud cair merepresentasikan kecepatan dan ketegangan pada model-model yang berorientasi sporty.

Sementara itu, permukaan dengan garis tegas dan bentuk pahatan yang terinspirasi dari es kutub padat menjadi dasar bagi model-model kendaraan mewah masa depan. Konsep sporty dan kemewahan bukanlah dua bahasa desain yang terpisah, melainkan dua ekspresi dari estetika yang sama. Dengan demikian, bahasa desain tersebut dapat diterapkan pada berbagai kategori kendaraan.

EX9 merupakan model pertama yang sepenuhnya mewujudkan bahasa desain ini di segmen kendaraan mewah. Jarak sumbu roda yang panjang, overhang depan yang pendek, dan bodi yang tegak menciptakan postur SUV unggulan yang mantap. Gagang pintu yang rata dengan permukaan bodi dan garis bahu yang menyambung tanpa putus membentuk siluet menyerupai pahatan. Desain ini menonjolkan proporsi, material, dan permainan cahaya dengan ornamen seminimal mungkin.

EX8 menonjolkan garis-garis horizontal dan menawarkan ruang kabin yang lapang bagi konsumen SUV premium yang bepergian bersama keluarga atau rombongan. Sementara itu, EX7 mengusung elemen desain EX9 dalam bentuk yang lebih sporty. MPV Concept mengeksplorasi bentuk-bentuk desain yang melampaui sedan dan SUV konvensional, sekaligus menunjukkan fleksibilitas konsep Kemewahan Masa Depan untuk berbagai kategori kendaraan.

ES GT mengekspresikan sisi yang lebih dinamis dari konsep Kemewahan Masa Depan. Sebagai crossover wagon pertama EXEED, bodinya yang rendah dan memanjang menciptakan kesan seolah-olah kendaraan sedang bergerak maju, bahkan saat diam. Di bagian interior, kokpit simetris dengan desain melengkung dilengkapi Sky Screen dan layar tengah yang melayang. Sementara itu, jok sport terintegrasi memberikan penopang samping aktif. Desain sportynya juga tercermin dalam pengalaman berkendara, menghadirkan DNA balap EXEED ke dalam kabin.

Setelah acara tersebut, tim desain mengadakan lokakarya bersama perwakilan pengguna dari berbagai negara. Masukan mereka akan membantu EXEED memahami kebutuhan pengguna dengan lebih baik. Dengan memanfaatkan teknologi parkir pintar SIVP, Texxeract, dan DNA balapnya, EXEED tengah membentuk visi baru tentang mobilitas di pasar global melalui desain, performa, dan teknologi mutakhir.

Global Pharmaceutical Company Commits to a Dual-Site Deal with AGC Biologics Exceeding EUR 0.5 Billion

Tue, 03 Nov 2026 18:55:00 +0700

Agreement builds on customer's long-term deal in new Yokohama facility for five commercial biologics programs, now allocating an additional six commercial programs to Copenhagen facility to consolidate high-volume, single-use biologics manufacturing with one global partner

Deal reflects a shared belief that site interoperability and dual submissions are key to unlocking the benefits of local manufacturing for a global supply

Running multiple sites as one integrated supply node lets both companies move production quickly between locations as needs change

COPENHAGEN, Denmark, Nov. 03, 2026 (GLOBE NEWSWIRE) -- AGC Biologics has expanded its existing long-term manufacturing agreement with a global pharmaceutical company, adding a second supply node at the CDMO's Copenhagen facility. The expansion, which builds on the existing agreement anchored at AGC Biologics' Yokohama site, grows the deal's total value beyond EUR 0.5 billion.

The expanded deal calls for multi-product drug substance manufacturing across six biologics programs at AGC Biologics' Copenhagen site, encompassing process transfer, scale-up, validation, and commercial production. Products will launch and move across facilities with several dual regulatory submissions to optimize capacity, cost, and local manufacturing benefits, capturing levels of flexibility and supply chain robustness that could not be achieved with a single-site supply arrangement.

"This customer is building a more resilient, more flexible supply chain, and they've chosen to do that with us across two continents. This is exactly what we're well-positioned to offer to a market craving geographic flexibility and regionalization, while retaining global supply," said Alberto Santagostino, President and CEO of AGC Biologics. "We've built our single-use strategy around quality, capacity, and deep technical expertise so that when a partner is ready to localize and scale, we can meet them where they are. This deal takes inter-site flexibility to a larger scale, but it builds on our existing experience: two of our customers have already decided to co-launch their products from both our Seattle and Copenhagen facilities."

This agreement further cements AGC Biologics as a prominent global player in single-use bioreactor manufacturing, serving the large-scale mammalian single-use manufacturing needs of major pharmaceutical companies across regions. AGC Biologics maintains one of the largest global networks of single-use manufacturing capacity by volume in the industry, according to BDO's bioTRAK database.

By combining strong commercialization capabilities with a friendly and expert CDMO approach, AGC Biologics supports customers pursuing cross-site launches, geographic flexibility, and regionalized manufacturing strategies across its global network.

"For a customer to bring six additional programs to Copenhagen, after bringing five to Yokohama, tells you everything about the trust our team has earned across the network," said Tadashi Murano, President of AGC Life Science Company. "Our focus stays on building lasting and trust-based relationships with our pharmaceutical customers, like we have been doing for decades in AGC with our industrial partners across a wide range of industries including electronics and automotive."

Frequently Asked Questions (FAQs)

Why isn't the customer named in this announcement?

Consistent with standard practice in the biopharmaceutical industry, customer names are not disclosed without the customer's consent. AGC Biologics regularly enters into confidential manufacturing agreements to protect its customers' competitive and regulatory strategies.

Could this customer expand its manufacturing relationship with AGC Biologics further?

AGC Biologics operates GMP manufacturing sites across the U.S., Europe, and Asia, providing capacity for customers to expand into additional regions as their commercial manufacturing needs evolve.

What does AGC Biologics' Copenhagen site offer to large-scale developers?

Scientific teams at AGC Biologics' Copenhagen site have 25 years of expertise in drug substance development and GMP manufacturing. Customers using the site have received a total of over 50 commercial approvals from more than 20 regulatory agencies.

The Copenhagen site expansion in 2024 included 18,000 square meters distributed across manufacturing, quality control laboratories and technical and warehouse areas, including:

Eight 2,000-liter single-use bioreactor production lines

One 500-liter perfusion bioreactor

Two downstream purification lines

About AGC Biologics

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells.

Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com.

Arla Foods Ingredients and wheyco to exhibit together at Fi Europe under 'Growing Stronger Together' theme

Tue, 03 Nov 2026 18:51:00 +0700

FRANKFURT, Germany, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Arla Foods Ingredients and wheyco, DMK Group's whey business, are to exhibit together at a trade event for the first time since the merger of their parent companies.

On 1st June, Arla Foods and DMK Group came together to form Europe's largest dairy cooperative. At Fi Europe (17th-19th November in Frankfurt), Arla Foods Ingredients, a subsidiary of Arla Foods, will demonstrate how the merger has created a stronger ingredients business.

The DMK Group and Arla Foods Ingredients stands will be located opposite one another, both carrying the message 'Growing Stronger Together', with DMK's subsidiary wheyco represented on the Arla Foods Ingredients stand.

Anne Widart, Vice President, Commercial, at Arla Foods Ingredients said: "One of the many benefits of the merger has been the creation of an ingredients powerhouse. It has unlocked new synergies and opportunities, allowing us to build something even better for the future. Fi Europe is the perfect platform to demonstrate our shared ambitions."

Earlier this year, Arla Foods Ingredients debuted its 'Targeted GLP-1 Companion Nutrition' concept, demonstrating how nutrient-dense products can meet the needs of GLP-1 users. At Fi Europe, it will showcase new applications, including a spoonable yogurt, a drinking yogurt, a fermented high-protein shot and a high-protein water-based shot.

The 'Unlock Permeate' concept will demonstrate how Arla Foods Ingredients' Variolac can improve cost-effectiveness and sensory properties in dairy, bakery and confectionery applications. Produced through nanofiltration, the whey permeate ingredient offers a mild milky taste, high cost efficiency and high content of calcium, magnesium and potassium.

Visitors can also sample new active nutrition solutions, including protein shakes, protein waters and the AirBar - an aerated milk protein bar with a light texture offering a new sensory experience in the protein bar category.

Anne Widart added: "These concepts typify Arla Foods Ingredients' commitment to innovation, from GLP-1 companion nutrition and active nutrition to improving taste and cost efficiency with whey permeate. With our expertise and capabilities further enhanced by the merger, we can deliver even greater value to our customers."

Meanwhile, DMK Industry will showcase its fat-filled ingredients, TOPPICS, FATTICS and BATTICS, and Sweetened Condensed Milk portfolios through four indulgent concepts: cupcakes with an aerated topping, chocolate caramel cookies, chocolate espresso fudge and a Cafe Bomb?n.

Arla Foods Ingredients will exhibit at Stand #30J94, opposite DMK Group at #30K94.

Philips delivers strong order intake growth, comparable sales growth and strong margin expansion in Q3; 2026 outlook reiterated

Tue, 03 Nov 2026 18:44:00 +0700

November 3, 2026

Q3 2026 Group performance

Comparable order intake increased by 8%, driven by strong Diagnosis & Treatment

Group sales of EUR 4.4 billion, reflecting 3% comparable sales growth

Income from operations of EUR 165 million

Adjusted EBITA margin increased 70 basis points to 13.0%, with expansion across all business segments

Operating cash flow of EUR 544 million; free cash flow of EUR 384 million

Respironics reached agreement in principle with the US Department of Justice

Philips reiterates its full-year 2026 outlook

Roy Jakobs, CEO of Royal Philips:

"We delivered an excellent 8% comparable order intake, led by broad-based order momentum in Diagnosis & Treatment, and 3% comparable sales growth in the third quarter, led by Personal Health and Connected Care. Our innovations and productivity measures drove continued margin expansion across all business segments.

We are executing our plan to accelerate profitable growth, with strong customer demand for our latest AI-enabled innovations, including our new CT platforms Verida and Rembra, our latest ultrasound system Alturion, and our HealthSuite Imaging cloud solution. These innovations demonstrate how our platforms bring together hardware, software, data and AI to create greater value for customers. We look forward to showcasing our next innovations at RSNA later this month.

We continue to make progress in resolving the consequences of the Sleep & Respiratory Care recall. The Respironics agreement in principle with the US Department of Justice marks an important step in this process.

Our year-to-date results, together with our strong order book, give us confidence in delivering our full-year outlook and achieving our medium-term ambitions. As we move forward in collaboration with customers, our hardworking teams around the world are focused on putting quality at the heart of our operations as we deliver better care for more people."

Group and segment performance

Comparable order intake grew 8%, driven by strong growth in Diagnosis & Treatment. Comparable sales increased by 3%, driven by Personal Health and Connected Care.

Adjusted EBITA margin increased 70 basis points to 13.0%, mainly driven by higher sales, higher gross margin and productivity measures, partly offset by cost inflation. Net cash flows from operating activities increased to EUR 544 million, mainly driven by higher cash earnings and lower working capital outflows. Free cash flow increased to EUR 384 million.

Diagnosis & Treatment comparable sales growth was flat. Growth in Image Guided Therapy was offset by a decline in Precision Diagnosis, mainly due to phasing of Ultrasound sales and lower sales in China as previously communicated at Q2. Adjusted EBITA margin increased 50 basis points to 12.3%, mainly driven by gross margin from innovation and productivity measures, partly offset by cost inflation.

Connected Care comparable sales increased by 5%, driven by growth in all businesses. Adjusted EBITA margin increased 190 basis points to 13.3%, mainly driven by higher sales, higher gross margin, and productivity measures, partly offset by cost inflation.

Personal Health comparable sales increased by 8%. Adjusted EBITA margin increased 60 basis points to 17.7%, mainly driven by higher sales and productivity measures, partly offset by advertising and promotion spend.

Innovation highlights

Philips is accelerating innovation in image-guided therapy. In the Netherlands, Philips is investing EUR 50 million in AI, robotics and advanced imaging, alongside over EUR 100 million from the Dutch government and a further EUR 150 million in private financing by Invest-NL and institutional investors, including pension funds. In the US, an ARPA-H award of up to USD 34 million will support AI-enabled robotic stroke care on the Azurion platform.

The Philips-coordinated European COMBINE-CT project advanced into clinical validation, launching five clinical studies to evaluate an integrated care pathway enabled by AI-powered CT and Spectral CT imaging solutions.

Philips extended its monitoring partnership with one of the largest US health systems through 2034. The national agreement covers equipment and services, expands the use of Philips' Capsule platform, and supports future technology needs.

Ontario Health in Canada selected the Philips Enterprise Imaging Vendor Neutral Archive to modernize province-wide imaging infrastructure and connect patient information across care settings. This Vendor Neutral Archive will support the sharing of more than 20 million imaging studies annually across more than 150 hospitals and 50 imaging clinics, helping enable a holistic patient view and more timely access to care.

Philips is supporting major healthcare programs in Latin America, including the modernization of 50 public hospitals in Venezuela, and an expanded partnership with Mexico's largest public healthcare institution, IMSS. The projects bring advanced imaging, image-guided therapy and monitoring technologies to more patients, expanding access to diagnostic, cardiac, neurological and stroke care.

Philips signed a long-term strategic partnership with Asia Medical Group to advance integrated cardiovascular care in China. The partnership will focus on clinical care, training, research and international collaboration, combining Philips' diagnostic imaging and image-guided therapy capabilities with Asia Medical Group's cardiovascular expertise.

Personal Health launched innovations across oral care, beauty and mother and child care. These include the AI-powered Sonicare DiamondClean 9900 Prestige, the first at-home IPL with real-time guidance Lumea 9900 Pro, and Philips Avent's first fully wearable Natural Care breast pump, bringing more personalized and premium solutions to consumers.

Productivity

Disciplined cost management and productivity initiatives delivered EUR 170 million in net savings in the quarter and EUR 427 million year-to-date. The company remains on track to deliver EUR 1.5 billion in savings under its 2026-2028 productivity program.

Progress on Respironics-related legal proceedings

Philips Respironics reached an agreement in principle with the US Department of Justice (DOJ) to resolve the previously disclosed criminal and civil investigations related to the Respironics recall. As a result, Philips recorded a provision of EUR 288 million in the third quarter of 2026. The settlement is subject to finalization of the relevant documentation; payment is expected in the first quarter of 2027.

Also in the third quarter, the Enterprise Chamber of the Amsterdam Court of Appeal denied requests from certain investors for an investigation into the affairs of Philips in connection with the Respironics recall.

Outlook

Philips reiterates its full-year 2026 outlook:

Comparable sales growth: 3%-4.5%

Adjusted EBITA margin: 13.5%-14.0%, including a US tariff refund benefit of approximately 1%

Free cash flow: EUR 1.5-1.7 billion, including a net US tariff refund benefit of approximately EUR 200 million

Within the context of an uncertain macro-environment, Philips' 2026 outlook includes currently known tariffs and assumes payment of the US Department of Justice settlement in the first quarter of 2027. The outlook excludes other ongoing Philips Respironics-related proceedings, including the investigation by the US State Attorneys General.

Capital allocation

In the third quarter, Philips issued EUR 650 million fixed rate notes due 2034 (the "Notes") under its European Medium Term Note program. The Notes are the healthcare industry's first EU Green Bond under the new European Green Bond Standard and were 2.7 times oversubscribed, reflecting strong investor demand. An amount equivalent to the gross proceeds will be used to finance taxonomy-aligned economic activities as referred to in the Philips European Green Bond Factsheet, supporting Philips in delivering on its 2030 Impact Ambitions. See here for more information on Philips' current debt structure.

Further information: conference call, video webcast and website

Roy Jakobs, CEO, and Charlotte Hanneman, CFO, will host a conference call for investors and analysts at 10:00 am CET on November 3, 2026, to discuss the results. A live webcast will be available on the Philips Investor Relations webpage and can be accessed here. A replay and related materials, including additional information on the outlook and forward-looking statements, will be available on the Philips Investor Relations webpage.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,900 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements and other information

Forward-looking statements

This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA*, future restructuring and acquisition-related charges and other costs, future developments in Philips' organic business and the completion of acquisitions and divestments. Forward looking statements can be identified generally as those containing words such as "anticipates", "assumes", "believes", "estimates", "expects", "should", "will", "will likely result", "forecast", "outlook", "projects", "may" or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

These factors include, but are not limited to, macro-economic and geopolitical changes - including the war in Ukraine and ongoing tensions in the Middle East - as well as measures such as enacted and proposed tariffs and trade actions introduced in response to rising global tensions; Philips' ability to keep pace with the changing health technology environment; Philips' ability to gain leadership in artificial intelligence and health informatics in response to developments in the health technology industry; integration of acquisitions and their delivery on business plans and value creation expectations; ability to meet expectations with respect to ESG-related matters; securing and maintaining Philips' intellectual property rights, and unauthorized use of third-party intellectual property rights; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; the resilience of our supply chain; challenges in simplifying our organization and our ways of working; attracting and retaining personnel; breach of cybersecurity; challenges in driving operational excellence and speed in bringing innovations to market; treasury and financing risks; tax risks; reliability of internal controls; compliance with regulations and standards involving quality, product safety, (cyber) security and artificial intelligence; and compliance with business conduct rules and regulations including privacy, existing and upcoming ESG disclosure and due diligence requirements. As a result, Philips' actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Further information chapter included in the Annual Report 2025.

Third-party market share data

Statements regarding market share contained in this document, including those regarding Philips' competitive position, are based on outside sources such as specialized research institutes, as well as industry and dealer panels, in combination with management estimates. Where information is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management's estimates of rankings are based on order intake or sales, depending on the business.

Market Abuse Regulation

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Use of non-IFRS information

In presenting and discussing the Philips Group's financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2025.

Presentation

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2025. Certain prior year balances have been reclassified to conform to the current period presentation.

Wood Mackenzie: Middle East conflict reshapes growth, resilience and partnerships across the region's largest NOCs

Tue, 03 Nov 2026 18:38:00 +0700

LONDON/HOUSTON/SINGAPORE, Nov. 03, 2026 (GLOBE NEWSWIRE) --

FOR IMMEDIATE RELEASE

Wood Mackenzie | www.woodmac.com

The Middle East conflict has tested ADNOC, Saudi Aramco and QatarEnergy, while highlighting sharp differences in export flexibility and portfolio diversification. Although all three companies remain resilient, the conflict has increased competing demands on capital, expertise and management attention, strengthening the role of partnerships at home and abroad.

Bypass routes, ship-to-ship shuttle transfers and a partial reopening of the Strait of Hormuz have allowed Aramco and ADNOC to increase combined operating cash flow by around $35 billion, or 25%, against pre-war estimates.

But the recovery remains fragile and bypasses carry their own risks, as Houthi attacks on the East-West pipeline and Red Sea shipping have shown. Flows through the Strait are only partly restored and the windfall depends on elevated prices. QatarEnergy has taken the biggest hit, just as the North Field expansion was due to lift liquefaction capacity from 77 to 142 mmtpa.

In the near term, all three NOCs are focused on restoring capacity and strengthening export resilience. Over the longer term, the conflict will reshape business development priorities - domestic resource access, partnerships and M&A - both at home and abroad.

"The conflict has increased the number of competing priorities facing Middle East NOCs," said Neivan Boroujerdi, Director, Corporate Research, Wood Mackenzie. "ADNOC, Aramco and QatarEnergy all face different challenges, but each is balancing domestic expansion, international growth and resilience simultaneously. Capital is not the constraint. Access to technology, markets and operational capability will shape the next phase, strengthening the role of partnerships across the sector."

Key findings:

ADNOC is leading the recovery. Freed from OPEC quotas, it is looking beyond its 5 million b/d target for 2027, with 6 million b/d mooted for the early 2030s. Hopes rest on unconventionals and additional phases at existing concessions. Its global LNG platform, formed in July 2026, targets 47 mmtpa of marketable LNG by 2035, which would rank it in the top five globally on LNG capacity. Delivering oil growth, gas self-sufficiency and international expansion simultaneously is likely to increase reliance on strategic partners and technical expertise.

Saudi Aramco's domestic gas expansion, and potential LNG exports, may open part of its upstream sector to external participation for the first time. As unconventional gas ramps up, projected sales gas supply of around 180 bcm/y in the early 2030s would outpace domestic demand of around 130 bcm/y, a surplus that could support significant LNG exports. A standalone gas entity could ring-fence gas investment from the oil business and provide a new funding vehicle for domestic gas growth and international LNG opportunities. Equity in that entity could be offered to IOCs or NOCs facilitating LNG swaps, offtake agreements and other commercial arrangements.

QatarEnergy faces the greatest strategic challenge due to long-term facility damage, lost production and continued dependence on the Strait. Repair costs could trigger IOC contract extensions, with ExxonMobil among the most exposed. The outcome for IOCs remains uncertain, potentially increasing near-term costs while extending participation. Exploration remains central to QatarEnergy's international strategy, but it should also consider development-stage acquisitions that can accelerate production growth and build technical capability.

Background:

Interest among IOCs and international NOCs in Middle East resources will remain high. Uncertain and volatile environments make low-cost barrels attractive, and the Middle East has the lowest of the lot. The region already accounts for around 15% of the Majors' production today, rising to 17% by 2030. However, elevated geopolitical risk may lead some international companies to become more selective about future exposure and NOCs may need to widen their partnership pool to new entrants.

The conflict has reinforced the strategic rationale for international diversification in gas (ADNOC and Aramco) and exploration (QatarEnergy). But competition for non-Hormuz LNG and US gas will intensify, building on pre-war deals struck largely at or above Wood Mackenzie's base-case NPV10. Ultimately, internationalisation is becoming less about growth and more about resilience through diversification. As NOCs balance domestic expansion with international growth ambitions, collaboration with IOCs will be required across upstream, gas and LNG development.

You have received this news release from Wood Mackenzie because of the details we hold about you. If the information we have is incorrect you can either provide your updated preferences by contacting our media relations team. If you do not wish to receive this type of email in the future, please reply with 'unsubscribe' in the subject header.  

About Wood Mackenzie:

Wood Mackenzie is the global leader in analytics, insights and proprietary data across the entire energy and natural resources landscape. For over 50 years our work has guided the decisions of the world's most influential energy producers, utilities companies, financial institutions and governments. Now, with the world's energy system more complex and interconnected than ever before, sector-specific views are no longer enough.

That's why we've redefined what's possible with Intelligence Connected: the fusion of our unparalleled proprietary data with the sharpest analytical minds, all supercharged by Synoptic AI, to deliver a clear, interconnected view of the entire value chain. Our trusted team of 2,700 experts across 30 countries breaks siloes and connects industries, markets and regions across the globe to empower our customers to identify risk sooner, spot opportunity faster and make every decision with complete confidence.

Siam Piwat showcases the success of its China partnership strategy with Golden Week sales doubling and Thailand's only winner of Alipay+ Growth Award

Tue, 03 Nov 2026 11:55:00 +0700

Photo: Siam Piwat the prestigious Alipay+ Growth Award, making it the sole recipient from Thailand, and one of the only two countries in Asia recognized at Ant International's VOYAGE 2026 & Gala Dinner in Shanghai, China.

Expanding its global partnership ecosystem through strategic collaborations with Huawei and iQIYI enables Siam Piwat to seamlessly integrate technology, entertainment, and luxury, delivering an end-to-end tourism experience for high-value Chinese tourists.

BANGKOK, THAILAND - Media OutReach Newswire - 3 November 2026 - Siam Piwat Group, a leading developer and operator of world-class landmarks, including Siam Paragon, Siam Center, Siam Discovery, ICONSIAM, and Siam Premium Outlets Bangkok, has announced the remarkable success of its global partnership ecosystem strategy.

Through its collaboration with premier partners to expand its high-value tourist base and stimulate spending, Siam Piwat saw its Golden Week sales double year-on-year. Furthermore, the strong performance earned Siam Piwat the prestigious Alipay+ Growth Award, making it the sole recipient from Thailand, and one of the only two countries in Asia recognized at Ant International's VOYAGE 2026 & Gala Dinner in Shanghai, China.

Alipay+ is the unified wallet gateway of Ant International, connecting global wallets like Alipay (China) and other leading payment apps across Siam Piwat retail touchpoints, while offering direct user engagement and exclusive campaigns in-app.

This milestone is the outcome of partnerships with leading payment service providers, including Alipay+, WeChat Pay, and UnionPay, to curate targeted campaigns and exclusive privileges for Chinese travelers, particularly high-value visitors and enthusiasts of luxury products.

Building on this success, Siam Piwat has expanded its collaboration with global tech leader Huawei and China's leading entertainment platform iQIYI to bridge the platforms' user bases with travel and retail experiences in Thailand, engaging visitors throughout the entire customer journey, from pre-trip inspiration to on-site spending and activities at the destination.

Another distinctive highlight is Siam Piwat's collaboration with Trip.com, which connects travel offers on Ctrip's WeChat Mini Program with exclusive privileges at MINISO ICONSIAM. This allows Chinese tourists to enjoy special benefits even before they arrive in Thailand. This model enables us to engage Chinese travelers during the trip-planning stage, introducing them to Siam Piwat's shopping destinations and the privileges available through the ONESIAM Global Visitor Card.

Chinese Partnerships Drive Transaction Growth

Since 2018, Siam Piwat has collaborated with Alipay+ to develop and deliver marketing campaigns, exclusive privileges, and digital payment solutions for international visitors. In the first eight months of 2026, transactions via Alipay+ grew 2.3-fold, while the number of active users surged 2.5 times compared to the same period last year.

During the Golden Week holiday, Siam Piwat partnered with Alipay+ and WeChat Pay to launch exclusive campaigns and tailored promotions for Chinese visitors across retail shops and luxury brands. This initiative drove a 100% year-on-year surge in sales, demonstrating the effectiveness of partnerships in boosting tourist spending.

As a result of these achievements, Siam Piwat was honored with the Alipay+ Growth Award as the sole winner from Thailand, one of the only two countries in Asia recognized at the VOYAGE 2026 & Gala Dinner in Shanghai, underscoring its success in driving digital transaction growth alongside its partners.

Partnership with Huawei for Pre-Arrival Engagement

Siam Piwat has expanded its tech alliance with Huawei to access Chinese consumers across their smartphone and wearable devices. This integration connects users directly to the ONESIAM Global Visitor Card, a digital membership card through which travelers can register, discover information, plan shopping itineraries, and unlock privileges from premier brands even before departing for Thailand.

Furthermore, travelers can sign up via a one-click WeChat Mini Program, minimizing repetitive form-filling and offering greater convenience. International visitors from other countries can also register via the official website or Huawei Wearables.

This initiative forms part of Siam Piwat's pre-arrival engagement strategy, designed to build brand awareness and inspire travelers right in the home country before their actual experiences at Siam Piwat's five landmarks. The program also offers year-round "always-on" privileges, ranging from best deals and luxury retail campaigns to exclusive offers, extending benefits beyond peak travel seasons.

Joining Forces with iQIYI to Attract Chinese Fans Through Fandom Marketing

Siam Piwat has also joined forces with iQIYI, China's leading streaming platform with premium Asian content, to spearhead a fandom marketing strategy under the concept of "From Screen to Real-World Experience," capitalizing on the popularity of Chinese artists and entertainment content to generate motivation for a trip to Thailand.

Among the pilot activities was the iQIYI Starship: Spring of The Blade Meet & Greet, which brought Chinese superstar Xu Kai to meet fans at Siam Paragon. The event generated massive social media buzz and expanded brand visibility across fan communities in mainland China and around the world. By connecting iQIYI's fan base to real-world experiences at Siam Paragon, the partnership has enhanced destination recall and inspired travel, particularly among younger generations of tourists.

Expanding the Global Ecosystem to Unlock New Growth Opportunities

Siam Piwat has been working actively to expand its global ecosystem through alliances with leading international partners across technology, tourism, payment solutions, and entertainment, including Huawei, iQIYI, Trip.com, Alipay+, WeChat Pay, and UnionPay, with the ultimate goal of connecting travelers to its ecosystem throughout every phase of their journey, from pre-trip planning to dining, lifestyle activities, and shopping in Thailand.

Furthermore, Siam Piwat is enhancing campaigns and exclusive privileges for high-spending travelers, especially in the luxury segment, to maximize spending potential and reinforce Siam Paragon and ICONSIAM's positions as premier luxury shopping destinations in the region.

This strategy reinforces Siam Piwat's position as a global destination and ecosystem developer and a partner of choice for leading global enterprises. By transforming partnership networks into concrete business results, Siam Piwat continues to attract high-quality tourists, increase spending value, and create growth opportunities for Thailand's tourism economy.

For more information and exclusive privileges via the ONESIAM Global Visitor Card, please visit:

Website: https://tourist.onesiam.com/en/tourist-card-privileges/

Instagram: https://www.instagram.com/onesiamglobal/

Siam Piwat

Siam Piwat is a leading retail and real estate developer behind Bangkok's most iconic destinations, including Siam Paragon, Siam Center, Siam Discovery, ICONSIAM, and Siam Premium Outlets Bangkok, globally recognized for pioneering experiential destinations.

For over six decades, Siam Piwat has been renowned for creating iconic destinations and world-class experiences, continuously redefining Bangkok's retail landscape through award-winning developments that set new global benchmarks. Guided by creativity, innovation, and sustainability, the company continues to lead with a bold vision that inspire, engage, and delight customers from around the world, while creating long-term value for society, businesses, and future generations.

The issuer is solely responsible for the content of this announcement.

Hashtags: #SiamPiwat #ONESIAMGlobalVisitorCard #ONESIAMGlobal #GlobalPartnershipEcosystem #GlobalDestination #TourismEconomy

https://www.siampiwat.com/en/home

https://www.linkedin.com/company/siam-piwat/

https://www.facebook.com/siampiwat.official/

https://www.instagram.com/siampiwat_official/

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Tue, 03 Nov 2026 11:48:00 +0700

Singapore's NPM Programme Three Phases

SG-INSIGHT study will extend whole- genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system

SINGAPORE - Media OutReach Newswire - 3 November 2026 - Illumina, Inc. (Nasdaq: ILMN) today announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) programme.

Expected to include approximately one in 10 Singapore residents, or around 450,000 individuals, the study is designed to generate evidence from genomic and health data to help inform preventive approaches to healthcare.

The study marks an important and planned transition from studying genomics primarily in healthy volunteers to studying those with a broad range of medical conditions. By connecting genomic information with real-world health data, SG-INSIGHT aims to better understand disease and treatment responses, support the responsible introduction of genetic screening in Singapore's public healthcare system, and help healthcare become more tailored to individuals over time.

"Singapore is showing what the future of precision medicine can look like at national scale," said Jacob Thaysen, Chief Executive Officer of Illumina. "By bringing genomic information closer to everyday healthcare, this programme has the potential to advance understanding of disease, generate evidence that support more informed care decisions, and ultimately move healthcare toward earlier, more precise intervention. We are proud to bring Illumina's technology, expertise and longstanding presence in Singapore to help make that vision possible."

"Phase III builds on nearly a decade of precision medicine in Singapore," said Professor Patrick Tan, Executive Director of PRECISE. "By extending the programme to patients across the public healthcare system, SG-INSIGHT aims to deepen understanding of how genetic, lifestyle and environmental factors are associated with health and disease. Phase III reflects Singapore's ambition to build a trusted and sustainable precision health ecosystem grounded in the needs and diversity of its population."

Illumina will perform the sequencing in Singapore through its local genomics facility where scientific, laboratory and bioinformatics teams will oversee sample preparation, sequencing, and genomic data analysis. Co-located with Illumina's manufacturing and R&D operations, the facility will seek the necessary accreditation and comply with Singapore's Healthcare Services Act 2020 (HCSA), strengthening its commitment to quality, safety, regulatory compliance and biomedical innovation.

Illumina's selection for the SG-INSIGHT Study was awarded through an international competitive tender. It builds on an existing multi-year engagement, through which Illumina supported the successful implementation and delivery of NPM Phase II, PRECISE-SG100K, covering more than 100,000 genomes from healthy volunteers.

"For nearly two decades, Singapore has been one of Illumina's most important centres for innovation, manufacturing and talent in Asia Pacific," said Nilesh Shah, Head of Region, Asia Pacific, Illumina. "Our long-standing relationship with PRECISE represents the next chapter in that commitment - combining Singapore's leadership in precision health with Illumina's local genomic capabilities and regional expertise. We remain committed to investing in the people, technology and partnerships that can help advance genomics responsibly in Singapore and across the region."

Illumina established its presence in Singapore in 2008. Today, Singapore serves as the company's Asia Pacific regional headquarters and one of its largest hubs outside the United States, with more than 1,700 employees across three locations. Illumina operations in Singapore encompass commercial operations, manufacturing, and R&D, supporting global research and innovation across sequencing platforms, software, and emerging technologies.

About PRECISE

Precision Health Research, Singapore (PRECISE) is the national central entity coordinating Singapore's multi-phase National Precision Medicine (NPM) programme. Established to drive a whole-of-Singapore effort, PRECISE works with research, clinical and industry partners to generate insights into Asian genomics and translate these into better health outcomes and economic opportunities.

PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore. NPM Phase II is supported by the National Research Foundation, Singapore (NRF) under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734).

www.npm.sg

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

The issuer is solely responsible for the content of this announcement.

Hashtags: #Illumina #PRECISE

Vision Action Fund Awards 24 Governments $10M+ to Transform Basic Eye Care and Expand Reading Glasses Access

Tue, 03 Nov 2026 07:17:00 +0700

Awarded governments will make vision screening, specialist referral and reading glasses part of the health services people already use

Antigua and Barbuda, Nov. 02, 2026 (GLOBE NEWSWIRE) -- More than 2 billion people globally live with vision impairment. For 1 billion of them, their sight loss is entirely preventable or treatable, but basic eye care is often unaffordable or inaccessible.

Announced today, Vision Action Fund is committing a minimum of $10 million in multi-year catalytic funding to 24 governments to integrate near-vision services and basic eye care into their healthcare systems and expand access to eyeglasses. The Global Vision Impact Awards were presented at the Global Summit for Eye Health by Vision Action Fund and Vital Strategies.

"Integrating basic eye health services into community health and primary healthcare ensures people get the continuity of care they need throughout their lives," said Abigail Steinberg, Executive Director, Vision Action Fund. "Our gratitude to the Government of Antigua and Barbuda, The International Agency for the Prevention of Blindness (IAPB), and World Health Organization for hosting the first-ever Global Summit for Eye Health and for your foundational and unwavering dedication to bring eye health to everyone, everywhere."

The awarded governments include Bangladesh, Cambodia, Cameroon, Chad, Ethiopia, Ghana, Madhya Pradesh (India), Indonesia, Kenya, Malaysia, Mauritania, Mexico, Mozambique, Nepal, Nigeria, Peru, Rwanda, Somalia, South Africa, Sri Lanka, Sudan, Uganda, Vietnam, and Zambia.

"I am encouraged by the commitment governments are making to improving access to essential eye care, and what this will mean for millions of people whose livelihoods and quality of life depend on clear vision," said Dr. Mary-Ann Etiebet, President and CEO, Vital Strategies. "By integrating basic eye care into primary health care, including routine screening for conditions such as diabetes and hypertension, governments can reach more people, identify vision problems earlier, and expand access to affordable solutions. We are proud to work alongside Vision Action Fund in partnership with governments to strengthen the policies and systems needed to make these commitments a sustainable reality."

Costing less than US$1 to make, reading glasses can increase personal income up to 33%, but policy and regulatory barriers deny access to hundreds of millions. The Global Vision Impact Awards operate in two phases. In the first, governments enact policies that expand access to primary eye care, such as: authorizing over-the-counter sales of reading glasses; expanding the network of primary and community health workers who can screen, refer, and dispense reading glasses; and eliminating tariffs and taxes on glasses.

In the second phase, countries scale up implementation nationally. The Vision Action Fund and partners will provide additional support and a supply of reading glasses for people living with age-related near-vision loss, or presbyopia. Once these strategies scale, governments could reach more than 100 million people and unlock tens of billions in economic productivity.

"For millions of Nigerians, including an estimated 25 million with presbyopia, eye screening and reading glasses will soon be within reach at their local point of care," said the Honourable Minister of State for Health and Social Welfare, Dr. Iziaq Adekunle Salako. "Nigeria's Presidential Initiative has already provided reading glasses to more than 1 million people through primary healthcare channels, and we commit to expanding our reach to 3 million more people over the next 3 years. We are grateful for The Global Vision Impact Award, which recognizes this momentum and partners with us to expand even further, bringing screening, referral, and reading glasses to the last mile. With this initiative, we are demonstrating to the world an effective model for delivering primary eye care at scale."

"We must make eye health part of everyday health care, everywhere," said Peter Holland, CEO, International Agency for the Prevention of Blindness. "That's why we are proud to convene the first-ever Global Summit for Eye Health to transform the way the world sees the value of vision. We commend the governments who have made the social, economic and health commitments to build a world where millions of people have access to quality eye care. Together, they demonstrate growing recognition that investing in eye health is an investment in human potential, economic growth, and sustainable development."

Vision Action Fund partners with Vital Strategies and national and local governments in the awarded countries to integrate eye care into community-level services, streamline retail access to reading glasses, and align policies with the WHO's SPECS 2030 targets, which call for a 40 percentage-point increase in effective refractive error coverage by 2030.

About Vision Action Fund

Vision Action Fund is working to expand access to basic eye care and make reading glasses a routine, self-sustaining part of life across low- and middle-income countries. Incubated by the Livelihood Impact Fund, we partner with governments, health systems, community-based networks, and private markets to unlock investment, drive systems change, and help restore tens of millions of adults' livelihoods, income, and independence. Visit www.visionactionfund.org and follow us on LinkedIn.

About Vital Strategies 

Vital Strategies is a global health organization that believes every person should be protected by an equitable and effective public health system. We work with governments, communities and organizations around the world to reimagine public health so that health is supported in all the places we live, work and play. The result is millions of people living longer, healthier lives. 

To find out more, please visit www.vitalstrategies.org or follow us on LinkedIn.

onsemi to Acquire Ferric, Establishing Leadership in Power Delivery for Next-Generation AI Processors

Tue, 03 Nov 2026 07:11:00 +0700

Acquisition expands AI Data Center revenue opportunity

News Highlights:

*Establishes onsemi as a leader in integrated voltage regulator (IVR) technology with best-in-class power density required for next-generation AI processors

*Combines Ferric's engineering talent with expertise in magnetics and power conversion with onsemi's productization capabilities, operating scale and customer relationships

*Raises onsemi's 2030 AI data center revenue target by $500 million to greater than $3 billion, with acceleration thereafter

*Expected to be accretive to onsemi's long-term revenue growth, gross margin, and EPS targets at scale

SCOTTSDALE, Ariz., Nov. 02, 2026 (GLOBE NEWSWIRE) -- onsemi (Nasdaq: ON) today announced that it has entered into an agreement to acquire Ferric, Inc., an innovator in integrated voltage regulator (IVR) technology, for $600 million in cash, plus up to $175 million in contingent consideration upon achievement of certain revenue milestones.

The acquisition will strengthen onsemi's leadership in power delivery to AI processors by adding differentiated power density, efficiency and transient response capabilities, further enhancing the company's portfolio from grid to core. As a result, onsemi is raising its 2030 AI data center revenue target by $500 million to greater than $3 billion, and expects multi-year accelerated growth in its IVR business thereafter.

"The rapid growth of AI is reshaping the requirements for power delivery to increasingly capable and power-intensive processors," said Hassane El-Khoury, President and CEO of onsemi. "Combined with onsemi's broad power portfolio, this strategic acquisition will strengthen our leadership position while expanding our content opportunity and ability to support customers as AI processor architectures continue to evolve."

"Ferric was founded to rethink how power is delivered at the point of compute," said Noah Sturcken, Founder and Chief Executive Officer of Ferric. "We believe integrated power architectures will play an increasingly important role in the future of AI data centers. Joining onsemi gives us the scale, manufacturing capabilities and customer reach needed to accelerate adoption and bring these technologies into the mainstream."

AI Power Demands Accelerate the Transition to IVR

As processor power continues to scale, the industry is moving voltage regulation progressively closer to the processor to reduce losses, increase power density and respond faster to rapidly changing power demands. IVRs represent the next step in this evolution by integrating power conversion directly into the processor package or substrate.

Ferric is at the forefront of this transition with highly differentiated IVR technology that integrates the power controller, FETs, inductors and capacitors into a single compact package. This architecture reduces board area by 50-70% compared with conventional discrete voltage regulator solutions while delivering more power closer to the processor. As a result, customers can dedicate a greater share of system power to AI compute, improving tokens per watt for increasingly power-intensive processors. By adding these capabilities, onsemi is positioned for leadership in AI processor power delivery architectures.

Ferric brings more than a decade of specialized engineering expertise in integrated voltage regulation and advanced magnetics, backed by a portfolio of more than 40 patents. By combining Ferric's differentiated technology with onsemi's productization capabilities, operating scale and broad customer relationships, the acquisition will establish onsemi as a leader in power delivery to next-generation AI processors and advance the commercialization of these technologies at scale.

Transaction Details

Under the terms of the agreement, onsemi will acquire Ferric for $600 million in cash at closing, plus up to $175 million in additional cash consideration tied to the achievement of revenue milestones. The transaction will be funded with cash on hand. Approximately 50 Ferric employees, primarily located in New York and Silicon Valley, are expected to join onsemi. The transaction is expected to close by the end of 2026, subject to customary closing conditions, and is expected to be accretive to onsemi's long-term revenue growth and gross-margin targets at scale. onsemi expects no meaningful near-term financial impact from this transaction.

More Information

Investor Presentation

Advisors

Barclays served as exclusive financial advisor to onsemi. Morrison & Foerster LLP served as legal counsel to onsemi. UBS Investment Bank served as exclusive financial advisor and Cooley LLP served as legal counsel to Ferric, Inc.

About onsemi

onsemi (Nasdaq: ON) delivers intelligent power and sensing technologies that enable electrification, energy efficiency, safety, and automation across automotive, industrial, and AI data center end‑markets. With a highly differentiated and innovative product portfolio, onsemi helps customers solve complex challenges to achieve higher efficiency, improved performance, and lower system cost, while supporting a safer, cleaner, and more energy‑efficient world. The company is part of the S&P 500? index. Learn more at www.onsemi.com.

About Ferric

Ferric is a leading innovator in Integrated Voltage Regulator (IVR) solutions, specializing in advanced power conversion technologies designed to optimize power delivery in next-generation computing systems. By providing dynamic control over power at the core level, Ferric enables greater computational density, higher efficiency and smarter performance across a wide range of industries. With proven reliability and system-level impact, Ferric's solutions play a pivotal role in unlocking the potential of tomorrow's most demanding technologies.

onsemi and the onsemi logo are trademarks of Semiconductor Components Industries, LLC. All other brand and product names appearing in this document are registered trademarks or trademarks of their respective holders.

Caution Regarding Forward-Looking Statements:

This press release includes "forward-looking statements," as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

All statements, other than statements of historical facts, included or incorporated in this press release could be deemed forward-looking statements, particularly statements about the consummation and anticipated benefits of the proposed acquisition of Ferric, including but not limited to: forecasts about the pace, scale and direction of technological change and its impact on onsemi's total addressable market opportunity; statements about onsemi's ability to capitalize on such an opportunity; and the potential impact of each of the foregoing on onsemi's operating results and financial condition.

Forward-looking statements are often characterized by the use of words such as "believes," "estimates," "expects," "projects," "may," "will," "intends," "plans," "anticipates," "should" or similar expressions or by discussions of strategy, plans or intentions. All forward-looking statements in this document are made based on onsemi's current expectations, forecasts, estimates and assumptions and involve risks, uncertainties and other factors that could cause results or events to differ materially from those expressed in the forward-looking statements.

Certain factors that could affect our future results or events are described under Part I, Item 1A "Risk Factors" in the 2025 Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on February 9, 2026 (the "2025 Form 10-K") and from time to time in onsemi's other SEC reports. Readers are cautioned not to place undue reliance on forward-looking statements. onsemi assumes no obligation to update such information, which speaks only as of the date made, except as may be required by law.

Investing in onsemi's securities involves a high degree of risk and uncertainty, and you should carefully consider the trends, risks and uncertainties described in this document, onsemi's 2025 Form 10-K and other reports filed with or furnished to the SEC before making any investment decision with respect to onsemi's securities. If any of these trends, risks or uncertainties actually occurs or continues, onsemi's business, financial condition or operating results could be materially adversely affected, the trading prices of onsemi's securities could decline, and you could lose all or part of your investment. All forward-looking statements attributable to onsemi or persons acting on onsemi's behalf are expressly qualified in their entirety by this cautionary statement.

Make Celebrations Extraordinary: 1664 and CLOT Unveil the Next Chapter of the East-Meets-French Story in Asia

Tue, 03 Nov 2026 07:07:00 +0700

The latest partnership introduces limited-edition designs and curated experiences this festive season, bringing a new spirit of celebration to the region

HONG KONG SAR - Media OutReach Newswire - 2 November 2026 - Carlsberg Asia today announced the next chapter of 1664'spartnership with CLOT, launching the festive campaign "Make Celebrations Extraordinary" across the Chinese Mainland, Singapore, Malaysia and Vietnam from November 2026 through February 2027.

Building on the partnership's successful debut Hong Kong last year, 1664, the world's No. 1* French beer brand, and CLOT, the pioneering fashion label founded by Edison Chen, are expanding the East-Meets-French story to a wider audience. The partnership introduces limited-edition 1664 x CLOT beer cans and exclusive merchandise, alongside a series of curated experiences that bring Asia a new way to celebrate across cultures and occasions.

Arindam Varanasi, Commercial Vice President, Carlsberg Asia, said: "The success of our first collaboration with CLOT proved that when 1664 shows up in culture, consumers respond. This year, we are expanding the partnership into the Chinese Mainland which is our largest market - a further step in strengthening our premium portfolio in Asia. By fusing CLOT's dynamic energy with 1664's French heritage, we are bringing our 'unquestionably good taste' spirit to life and redefining celebration across the region."

Make Celebrations Extraordinary: From Design to Moments

At the heart of the campaign is CLOT's signature Silk Royale pattern, a motif inspired by the elegance of Chinese silk, its intricate geometric lines referencing luxurious jacquard with a modern edge. For this collaboration, the pattern is reimagined in vibrant festive hues, flowing across 1664's iconic blue-and-white design in a visual dialogue between Asian tradition and French audacity.

Anchored by 1664's signature cocarde, a nod to the brand's French heritage and brewing craftsmanship, the 1664 x CLOT design motifs commemorate this special time of year. Exclusively for this collaboration, the CLOT's iconic Silk Royale pattern is reimagined in a vibrant, multi-coloured treatment. Illuminated by neon-inspired outlines, the design evokes the glow and vibrant energy of Asia in blues, reds and yellows accented by firework patterns, capturing the uplifting moment when celebrations come alive with 1664.

The interplay between CLOT's richly coloured patterns and 1664's clean red, white and blue palette creates a contemporary elegance that captures the spirit of celebration in style, where East meets French and tradition meets modernity.

Beyond the beer cans, the 1664 x CLOT design motifs extend to a range of exclusive merchandise. The key highlight is a bespoke apparel collection curated by CLOT for the campaign, including T-shirts, socks and caps, each piece infused with festive vibrancy and the collaboration's East-meets-French spirit, bringing the partnership to life beyond the taste and into the moments people share.

The 1664 x CLOT limited-edition products are available from November 2026 through February 2027 in selected supermarkets, bars, restaurants and online across Chinese Mainland, Singapore, Malaysia and Vietnam. A series of on-the-ground activations and market-exclusive premiums will also be rolled out throughout the season, inviting consumers to immerse themselves in festive experiences that make their celebrations extraordinary. For more information, please visit https://www.1664blanc.com/.

*GlobalData 2025 research for 2023, based on actual volume sales data in The Hectolitres.

About Carlsberg

Established in 1847 by brewer J.C. Jacobsen, the Carlsberg Group is one of the leading brewery groups in the world, with an attractive portfolio of beer and other beverage brands. With over 37.000 employees, and with a presence in more than 150 markets, the Group has a purpose of brewing for a better today and tomorrow. Doing business responsibly and sustainably supports that purpose - and drives the efforts to deliver value for shareholders and society.

Carlsberg Asia is a dynamic and diverse region comprising of 8 operating markets: Cambodia, China, Hong Kong S.A.R. (Macau and Taiwan), Laos, Malaysia, Myanmar, Singapore and Vietnam. Altogether we have 35 breweries in operation and some 13,000 employees spreading across the Asian markets. The Asia Regional Office is based in Hong Kong.

About 1664

1664, the world's No.1 French beer brand with a rich heritage spanning over 350 years, epitomizes timeless yet playful elegance. Our brew is distinguished by its lively and refreshing taste profile, with signature citrus notes that deliver impeccable taste in every sip. Inspired by art, design and the French appreciation of life, 1664 elevates everyday moments, turning the ordinary into the extraordinary.

About CLOT

First established in 2003, CLOT is a pioneering streetwear label and the brainchild of Edison Chen. Conceived from the desire to bridge East and West through thoughtfully-designed apparel and goods, the brand takes its Chinese roots to a worldwide stage, modernizing, reinterpreting, and splices motifs from traditional Chinese culture with bold graphics, exaggerated silhouettes, and a dynamic energy reflective of the new youth of Asia. CLOT has since partnered with the likes of adidas, Bang & Olufsen, Coca-Cola, fragment design, Medicom Toy, Nike, Rimowa, Supreme, St?ssy, sacai and visvim to create sold-out collaborations, solidifying its international presence in the process.

CLOT's vision for a borderless culture of streetwear is further manifested in JUICE, a fashion and lifestyle retailer that expresses an all-encompassing aesthetic through its curation of apparel, home goods, and more. Located in major cities around the world, JUICE can be found in Hong Kong, Shanghai, Taipei, Taichung, and online.

The issuer is solely responsible for the content of this announcement.

Hashtags: #CarlsbergAsia

ETC Named to TIME's America's Growth Leaders 2027 List and the Philadelphia Business Journal's 2026 PHILLY's FAST 50

Tue, 03 Nov 2026 07:02:00 +0700

SOUTHAMPTON, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Environmental Tectonics Corporation (OTCID: ETCC) ("ETC" or the "Company") was named to TIME's annual list of America's Growth Leaders 2027, ranking 201 among the top 500 companies. This recognition distinguishes ETC for its outstanding growth, performance, and business momentum.

TIME and market research firm Statista, determined America's Growth Leaders through an analysis of publicly traded companies headquartered in the U.S. Each company was evaluated based on revenue growth, stock performance, and financial stability.

ETC was also recognized in the Philadelphia Business Journal's 2026 FAST 50 list, which highlights the fastest-growing companies in the Greater Philadelphia region. This is the second consecutive year that the Company has been recognized, ranking seventh both years.

Robert Laurent, ETC's President and CEO stated, "Being named one of TIME's America's Growth Leaders is an indicator of the success of the strategic efforts of our entire team, in each of our business units. We are equally honored to be recognized as one of the fastest growing companies in the Greater Philadelphia region for the second year in a row."

About ETC

ETC designs, manufactures, and sells software-driven products and services used to recreate and monitor the physiological effects of motion on humans, and equipment to control, modify, simulate and measure environmental conditions. Our products include aircrew training systems (aeromedical, tactical combat, and general), disaster management systems, sterilizers (steam and gas), environmental testing and simulation systems, and other products that involve similar manufacturing techniques and engineering technologies.

ETC's unique ability to offer complete systems, designed and produced to high technical standards, sets it apart from its competition. ETC's headquarters is in Southampton, PA. For more information about ETC, visit http://www.etcusa.com/.

Forward-looking Statements

This news release contains forward-looking statements, which are based on management's expectations and are subject to uncertainties and changes in circumstances. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements, and these statements may include terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "future", "predict", "potential", "intend", or "continue", and similar expressions. We base our forward-looking statements on our current expectations and projections about future events or future financial performance.

Our forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about ETC and its subsidiaries that may cause actual results to be materially different from any future results implied by these forward-looking statements. We caution you not to place undue reliance on these forward-looking statements.

Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-'286) Following Interim Futility Analysis

Tue, 03 Nov 2026 06:53:00 +0700

*Predictive Interim analysis indicates low probability of study meeting its primary efficacy endpoint if continued

*Comprehensive analysis and evaluation of available open-label extension data will follow

*No safety concerns were identified in the interim analysis

PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that it will discontinue the Phase 2 TOPAS-MSA study (NCT06568237) evaluating emrusolmin (TEV-'286) in adults with multiple system atrophy (MSA).

The decision follows a recommendation from the independent data monitoring committee (IDMC), based on a prespecified interim futility analysis. The analysis met the predefined futility criterion, indicating a low probability of the study meeting its primary efficacy endpoint if continued. This was an interim predictive assessment and not the study's final efficacy analysis. No safety concerns were identified in the interim analysis.

Emrusolmin is being developed in partnership with MODAG GmbH. A comprehensive analysis of the TOPAS-MSA data and available data from the open-label extension study of emrusolmin in MSA (NCT07197866) will follow. The decision announced today concerns TOPAS-MSA and does not represent a final decision on the broader emrusolmin program.

"While we are disappointed by the outcome of this interim analysis for the Phase 2 study, we remain deeply committed to learning everything we can from these data," said Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer at Teva. "We are deeply grateful to the patients, families, investigators, and study teams who contributed their time and commitment to this research. Our hope is that the science and learnings can deepen our understanding of MSA and help us determine a path forward for emrusolmin."

Teva will work with the TOPAS-MSA study investigators to ensure the study protocols are followed while the Phase 2 study is discontinued. Teva plans to share the TOPAS-MSA findings with the scientific community following completion of its comprehensive analysis.

Teva to Host Q3 Earnings Call on November 3, 2026

Teva will host its third-quarter 2026 earnings conference call on November 3, 2026 at 8:00 a.m. ET. Register here. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations.

About the TOPAS-MSA Program

TOPAS-MSA (NCT06568237; TV56286-NDG-20039) is a randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy and safety of emrusolmin in adults with multiple system atrophy (MSA). The study was designed to enroll approximately 350 participants to receive emrusolmin 300 mg or placebo for approximately 48 weeks, followed by a four-week follow-up period. The primary endpoint is change from baseline to Week 48 in the modified Unified Multiple System Atrophy Rating Scale Part I score.

The separate Phase 2 open-label extension (OLE) study (NCT07197866; TV56286-NDG-20041) is designed to evaluate the long-term safety and tolerability of emrusolmin in eligible participants who completed the 48-week treatment period of TOPAS-MSA.

About emrusolmin

emrusolmin, also known as TEV-'286, is an investigational, orally administered small molecule designed to target alpha-synuclein aggregation, one of the core pathogenic mechanisms believed to be involved in MSA. Emrusolmin is being developed in partnership with MODAG GmbH. The U.S. Food and Drug Administration granted Orphan Drug designation to emrusolmin for MSA in 2022 and Fast Track designation in September 2025.

About Multiple System Atrophy (MSA)

MSA is a rare neurodegenerative disorder classified clinically as "atypical parkinsonism" and belongs to the group of synucleinopathies. MSA is characterized histopathologically by abnormal deposits of the α-synuclein protein, mainly in oligodendroglial cells (glial cytoplasmic inclusions) and also in certain nerve cells. Typically, there is a dysfunction of the autonomic nervous system, i.e., disturbances of bladder function, erectile function, intestinal mobility, or the regulation of blood pressure in combination with a movement disorder.

The movement disorder often presents with either Parkinson-like symptoms or a disturbance of cerebellar function, such as ataxia, gait and speech problems. In the US, EU, and Japan, MSA affects about 40,000 people (prevalence of 4 per 100,000), with about 6,000 new cases diagnosed each year (incidence of 0.6 per 100,000). Post-diagnosis life expectancy is about 6-10 years. Due to the relatively small number of affected patients and lack of effective therapy, MSA qualifies for orphan status, allowing a shorter development path. This unmet medical need for MSA disease modification is the driver to develop new therapies that could potentially impact the lives of patients.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "developing," "target," "may," "expand," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future performance.

Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to develop emrusolmin (TEV-'286) for the treatment of MSA in adults; our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors," "Other Information" and "Cautionary Note Regarding Forward Looking Statements."

Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

YYForce Highlights US$21.9 Million in Reported Net Assets and Outlines Commercial Robotics and AI Platform Priorities

Tue, 03 Nov 2026 06:47:00 +0700

YYForce presents its reported book equity alongside its market capitalization to give investors additional context for its growth plans

SINGAPORE, Nov. 02, 2026 (GLOBE NEWSWIRE) -- YYForce Inc. (Nasdaq: YFOR) ("YYForce" or the "Company"), a technology-enabled provider of workforce solutions and integrated facility management services, today highlighted its reported net assets of approximately US$21.9 million, compared with an estimated market capitalization of approximately US$2.1 million as of October 30, 2026, and outlined its commercial robotics and AI priorities.

YYForce is providing this information to help investors evaluate its reported asset base alongside its operating results, liquidity and strategy across workforce platforms, integrated facility management and service robotics.

Reported financial position and valuation comparison

As reported in the Company's Form 6-K filed on September 25, 2026, YYForce's consolidated balance sheet as of June 30, 2026, showed the following amounts.

Balance sheet measure	Reported amount
Total assets	Approximately US$38 million
Equity attributable to YYForce shareholders (net assets)	Approximately US$21.9 million

As of October 30, 2026, the Company's estimated equity market capitalization was approximately US$2.1 million, equivalent to approximately 9.6% of reported equity attributable to YYForce shareholders. This represented a discount of approximately 90.4% to reported book equity. This information uses rounded amounts and reflects financial and market data from different dates.

Book equity does not represent unrestricted cash, tangible net assets, liquidation proceeds or an estimate of intrinsic value. Asset carrying values are subject to accounting estimates and impairment assessments. Investors should consider the full financial statements, including liabilities, operating results, cash flows and subsequent disclosures.

Management commentary

"We believe the difference between our reported book equity and public market capitalization warrants investors' attention," said Mike Fu, Chief Executive Officer of YYForce. "Our responsibility is to provide clear financial information and execute our commercial strategy. We remain focused on customer delivery, disciplined capital allocation and developing our workforce, facility management and service robotics businesses."

"We will evaluate each investment against customer demand, available liquidity, capital requirements and expected returns," Mr. Fu added.

Strategic growth priorities

Commercial robotics expansion. Pursuing service robotics deployments and integration with hospitality and enterprise workflows, with attention to customer requirements, deployment costs and ongoing support.

AI-enabled facility and workforce platforms. Developing digital platform capabilities and pursuing enterprise adoption to support workforce coordination, shift delivery and facility operations.

Capital discipline and market transparency. Evaluating commercial deployments against customer demand, capital requirements and expected returns, while providing shareholders with clear updates on material developments.

YYForce will continue to assess its operating performance, financing requirements and capital allocation priorities as its business develops. Future commercial progress remains subject to operational execution, customer adoption and broader market conditions.

About YYForce Inc.

YYForce Inc. (Nasdaq: YFOR) is a technology-enabled provider of workforce solutions and integrated facility management services. The Company is developing AI-enabled workforce platforms and robotics capabilities to support frontline operations, improve productivity and address evolving customer needs.

For more information, visit www.yyforce.ai.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on the Company's current expectations, assumptions and information available to it as of the date of this release. Forward-looking statements can be identified by words such as "may," "will," "should," "expects," "anticipates," "plans," "intends," "believes," "estimates," "potential" or similar expressions, or the negative of these terms.

Forward-looking statements in this release include, but are not limited to, expectations regarding the Company's strategy, commercial deployments, platform development, operational efficiency, capital allocation and future business performance. Historical financial figures are not forward-looking statements. Reported book equity is not an indication of the price at which the Company's shares may trade or of amounts that would be realized on any sale or liquidation.

Forward-looking statements involve inherent risks and uncertainties, and the forward-looking events discussed in this press release may not occur, actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about the Company and a number of factors. For a more detailed discussion of risk factors, please refer to the Company's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" section of the Company's most recent annual report on Form 20-F, as amended. YYForce undertakes no obligation to update these statements except as required by applicable law.

Descartes' Advanced Ocean Visibility Solution Now Integrated with SAP Transportation Platforms

Mon, 02 Nov 2026 21:03:00 +0700

WATERLOO, Ontario and ATLANTA, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that its Descartes MacroPoint Advanced Ocean Visibility solution is now integrated with SAP Business Netwoark Freight Collaboration and SAP Business Network Global Track and Trace through a standardized connection to the Descartes Global Logistics Network (Descartes GLN).

The combined solution provides shippers with access to expanded multimodal visibility capabilities within their SAP transportation environments.

"As supply chains become increasingly global, multimodal and disruption-prone, organizations require more timely and consistent visibility across transportation modes to improve planning and execution," said Dan Cicerchi, EVP, Corporate & Operations Development at Descartes. "By bringing our ocean visibility data directly into SAP's leading transportation platforms from the Descartes GLN, shippers can gain a more complete view of global shipments, improve operational responsiveness and strengthen supply chain resilience."

Ocean visibility data from the Descartes GLN flows into SAP Business Network Freight Collaboration and SAP Business Network Global Track and Trace, providing near real-time container-level tracking of departures, arrivals, loading events, gate movements and other critical milestones within customers' existing SAP workflows.

This creates a consistent visibility experience across both ocean and road transportation movements. By combining standardized APIs, harmonized data models, and continuously updated logistics event data, the combined solution simplifies deployment, delivers multimodal visibility at scale, and provides a trusted foundation for analytics, automation, and AI-driven supply chain innovation. The comprehensive testing program confirmed production-ready performance, reliable event exchange, accurate milestone tracking and robust support for complex shipment scenarios across the full shipment lifecycle.

The new end-to-end connection builds on the existing Descartes GLN integration with SAP Business Network Freight Collaboration, which supports processes such as carrier booking. Descartes MacroPoint Advanced Ocean Visibility is available on the SAP? Store.

SAP Store, found at store.sap.com, delivers a simplified and connected digital customer experience for finding, trying, buying and renewing more than 2,300 solutions from SAP and its partners. There, customers can find the SAP solutions and SAP-validated solutions they need to grow their business. And for each purchase made through SAP Store, SAP will plant a tree.

Descartes is a partner in the SAP PartnerEdge program. The SAP PartnerEdge program provides the enablement tools, benefits and support to facilitate building high-quality, disruptive applications focused on specific business needs ? quickly and cost-effectively.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices. All other product and service names mentioned are the trademarks of their respective companies.

Descartes Media Contact

Andra Schaz

aschaz@descartes.com

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws ("forward-looking statements") that relate to Descartes' solution offerings and potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, "Certain Factors That May Affect Future Results" in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities across Canada including Descartes' most recently filed annual and interim management's discussion and analysis which are available under Descartes' profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/.

If any such risks actually occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management's current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Except as required by applicable law, we do not undertake or accept any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.